<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metformin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metformin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metformin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9621" href="/d/html/9621.html" rel="external">see "Metformin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11790" href="/d/html/11790.html" rel="external">see "Metformin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709034"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (&gt;5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and increased lactate/pyruvate ratio; and metformin plasma levels generally &gt;5 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), ≥65 years, having a radiological study with contrast, surgery and other procedures, hypoxic states (eg, acute congestive heart failure), excessive alcohol intake, and hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the full prescribing information.</p>
<p style="text-indent:-2em;margin-left:2em;">If metformin-associated lactic acidosis is suspected, immediately discontinue metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F193858"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fortamet [DSC];</li>
<li>Glumetza;</li>
<li>Riomet;</li>
<li>Riomet ER [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867485"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Metformin;</li>
<li>APO-MetFORMIN;</li>
<li>APO-MetFORMIN ER;</li>
<li>Auro-Metformin;</li>
<li>DOM-MetFORMIN;</li>
<li>Glucophage;</li>
<li>Glumetza;</li>
<li>Glycon;</li>
<li>JAMP-MetFORMIN;</li>
<li>Mar-MetFORMIN;</li>
<li>MetFORMIN FC;</li>
<li>MINT-MetFORMIN;</li>
<li>NRA-Metformin;</li>
<li>PMS-MetFORMIN;</li>
<li>PMSC-Metformin;</li>
<li>PRO-MetFORMIN;</li>
<li>PRZ-Metformin;</li>
<li>RAN-MetFORMIN;</li>
<li>RATIO-MetFORMIN [DSC];</li>
<li>RIVA-MetFORMIN;</li>
<li>SANDOZ MetFORMIN FC;</li>
<li>Septa-MetFORMIN [DSC];</li>
<li>TEVA Metformin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060245"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiabetic Agent, Biguanide</span>;</li>
<li>
<span class="list-set-name">Antidiabetic Agent, Oral</span>;</li>
<li>
<span class="list-set-name">Hypoglycemic Agent, Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F193885"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment: Note:</b> Allow 1 to 2 weeks between dose titrations. Generally, clinically significant responses are not seen at doses less than 1,500 to 2,000 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359574'])">Ref</a></span>); however, a lower recommended starting dose with a gradual increase in dosage is recommended to minimize GI symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Children ≥10 years and Adolescents: Oral: Initial: 500 to 1,000 mg once daily <b>or</b> 500 mg twice daily; increase by 500 mg every 1 to 2 weeks as tolerated; maximum dose: 1,000 mg twice daily <b>or</b> 850 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359574','lexi-content-ref-ADA.2','lexi-content-ref-30425094','lexi-content-ref-36161685','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359574','lexi-content-ref-ADA.2','lexi-content-ref-30425094','lexi-content-ref-36161685','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i>
<b>Note: </b>Fewer GI effects may be seen with extended-release products; however, no pediatric studies have compared extended-release products to standard metformin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: Limited data available: Oral: Initial: 500 to 1,000 mg once daily for 7 days; may increase dose by 500 mg increments every 1 to 2 weeks as tolerated; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359574','lexi-content-ref-30425094','lexi-content-ref-36161685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359574','lexi-content-ref-30425094','lexi-content-ref-36161685'])">Ref</a></span>).<b> Note:</b> If glycemic control is not achieved at maximum dose, may divide dose and administer twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical patients</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2','lexi-content-ref-36537521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2','lexi-content-ref-36537521'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Minor surgeries (surgery lasting &lt;2 hours, with or without sedation or anesthesia, where rapid recovery is anticipated and patient is expected to be able to eat within 2 to 4 hours): Discontinue metformin the day of surgery; monitor glucose closely; administer rapid- or short-acting insulin if needed; resume metformin after oral intake is tolerated.</p>
<p style="text-indent:-2em;margin-left:6em;">Major surgeries (any surgery under anesthesia that is more than minor, typically lasting &gt;2 hours with a high likelihood of postoperative nausea, vomiting, and/or inability to adequately feed after procedure): Discontinue metformin the day of surgery; monitor glucose closely; administer rapid- or short-acting insulin if needed. Withhold metformin for 24 hours following surgery and until normal renal function has been confirmed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6c73539-3e00-4b71-951c-3b969bd58d1b">Obesity; severe, adjunct therapy with lifestyle interventions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obesity; severe, adjunct therapy with lifestyle interventions:</b> Limited data available; data have shown modest efficacy; reported mean BMI reduction −0.86 to −1.16 kg/m<sup>2</sup>, although reported efficacy endpoints/outcomes in trials are variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28359099','lexi-content-ref-24343296','lexi-content-ref-28632874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28359099','lexi-content-ref-24343296','lexi-content-ref-28632874'])">Ref</a></span>). Overall, due to limited efficacy, some experts do not consider metformin a weight loss treatment option for pediatric obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28359099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28359099'])">Ref</a></span>). Optimal treatment duration not established; duration in trials varied from 3 to 12 months. Daily multivitamin supplement may be considered with therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23185143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23185143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release: </i>Dosing regimens variable: Children ≥6 years and Adolescents: Oral: Initial: 500 mg once <b>or</b> twice daily, may titrate upward at weekly intervals by 500 mg/day increments; reported final doses: 1,000 to 2,000 mg/day in 2 divided doses; a meta-analysis showed that metformin 2,000 mg/day intervention was most identified as most effective relative to lower doses or lifestyle modifications in adolescents without diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30511328','lexi-content-ref-23175691','lexi-content-ref-28632874','lexi-content-ref-21228310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30511328','lexi-content-ref-23175691','lexi-content-ref-28632874','lexi-content-ref-21228310'])">Ref</a></span>). Age-dependent efficacy findings are conflicting; some data suggest that metformin may have greater efficacy in prepubertal children and others have shown a greater effect in pubertal subjects (11 to 17 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28759403','lexi-content-ref-30070925']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28759403','lexi-content-ref-30070925'])">Ref</a></span>). A low dose (850 mg/day) over a prolonged period (24 months) showed positive effects on body composition (weight and BMI standard deviation scores) and other metabolic and inflammatory markers (eg, fat mass, liver fat, leptin, highly sensitive C-reactive protein) in a small, placebo-controlled trial of 22 subjects (metformin=13; age range: 6 to 13 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31821361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31821361'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Adolescents: Oral: Initial: 500 mg once daily with dinner for 2 weeks; increase to 1,000 mg once daily for 2 weeks, and then 2,000 mg once daily; may slow titration if adverse GI effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20124139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20124139'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c19c9e3e-5f24-43a6-8f44-3700735bb7b2">Weight gain, atypical antipsychotic-induced; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight gain, atypical antipsychotic-induced; treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i>
<b>Note:</b> In trials, all patients were diagnosed with autism spectrum disorder; trials used metformin oral solution and slowly titrated the dose to minimize GI effects and maximize tolerability. After 16 weeks of therapy, patients receiving metformin had a statistically significant decrease in BMI z-scores (primary efficacy outcome) as well as other secondary outcomes (eg, raw weight, BMI) compared to placebo. A 16-week, open-label extension study showed results achieved in the treatment group were maintained without further decreases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27556593','lexi-content-ref-28942807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27556593','lexi-content-ref-28942807'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 9 years: Oral: Initial: 250 mg with evening meal for 1 week, then 250 mg twice daily for 1 week, then 500 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">10 to 17 years: Oral: Initial: 250 mg with evening meal for 1 week, then 250 mg twice daily for 1 week, then 500 mg twice daily for 1 week, then 850 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129337"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents: Oral: Immediate release, extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;45 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to 45 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Preexisting impairment: </i>Initiation of therapy is not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>During therapy:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If eGFR falls between 30 and &lt;45 mL/minute/1.73 m<sup>2</sup></i>: Consider risk/benefit ratio for continuing therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If eGFR falls to &lt;30 mL/minute/1.73 m<sup>2</sup>:</i>Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p></div>
<div class="block dohp drugH1Div" id="F51129338"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥10 years and Adolescents: Avoid metformin; liver disease is a risk factor for the development of lactic acidosis during metformin therapy.</p></div>
<div class="block doa drugH1Div" id="F193863"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9621" href="/d/html/9621.html" rel="external">see "Metformin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="889571cd-a4d9-44d4-9276-3864bbbc70bd">Antipsychotic-induced weight gain, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antipsychotic-induced weight gain, treatment (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Dosage range studied in trials: 750 mg to 2 g daily in 2 to 3 divided doses. Doses up to 2.55 g/day have also been used. To minimize GI adverse effects, most trials initiated therapy with 250 mg or 500 mg twice daily <b>or</b> 850 mg once daily, and increased the dose gradually based on tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17490862','lexi-content-ref-23759461','lexi-content-ref-22860242','lexi-content-ref-27716110','lexi-content-ref-23846733','lexi-content-ref-22398127','lexi-content-ref-26280837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17490862','lexi-content-ref-23759461','lexi-content-ref-22860242','lexi-content-ref-27716110','lexi-content-ref-23846733','lexi-content-ref-22398127','lexi-content-ref-26280837'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Maintenance dosage range in trials: 1 to 2 g once daily. To minimize GI adverse effects, trials initiated therapy with 500 mg once daily and titrated dosage upwards in 500 mg increments every 2 to 6 weeks based on tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19515536','lexi-content-ref-26872112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19515536','lexi-content-ref-26872112'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0f26e44f-57e5-4c7a-890e-4dc8160c0458">Diabetes mellitus, type 2, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For select patients with prediabetes, particularly for those with BMI ≥35 kg/m<sup>2</sup>, age &lt;60 years, and patients with prior gestational diabetes mellitus, in whom lifestyle interventions fail to improve glycemic indices (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Robertson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Robertson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 850 mg once daily for 1 month, then increase to 850 mg twice daily; unless GI adverse effects warrant a longer titration period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11832527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11832527'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients in whom glycemic targets are not met despite diet, exercise, and metformin, combination therapy is necessary to achieve optimal results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial: </i>
<b>Oral:</b> 500 mg once or twice daily <b>or</b> 850 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18945920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18945920'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustments:</i>
<b>Oral: </b>The dose should be increased gradually to minimize GI adverse effects. Titration strategies vary widely, but usually done in 500 mg or 850 mg increments every 7 days (range: 5 days to 1 month).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Usual maintenance dosage:</i>
<b>Oral: </b>1 g twice daily <b>or</b> 850 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18945920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18945920'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maximum:</i>
<b>Oral: </b>2.55 g/day. Modest additional benefit has been observed with doses up to ~2.5 g/day; however, GI adverse effects may limit use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18945920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18945920'])">Ref</a></span>). If doses &gt;2 g/day are needed, consider administering in 3 divided doses to minimize GI adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i>
<b>Oral: </b>500 mg to 1 g once daily</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustments:</i>
<b>Oral: </b>The dose should be increased gradually to minimize GI adverse effects. Titration strategies vary widely, but usually done in 500 mg increments every 7 days (range: 7 days to 6 weeks).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maximum:</i>
<b>Oral: </b>2 g/day. If glycemic control is not achieved at maximum dose given once daily, may divide maximum dose and administer twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a43e657-07db-4586-bed0-4f74c0c43dc1">Gestational diabetes mellitus, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational diabetes mellitus, treatment (alternative agent) (off-label use): </b>Immediate release<b>:</b>
<b>Oral:</b> Initial: 500 mg once or twice daily; increase dosage to meet glycemic targets, typically over 1 to 2 weeks, up to a maximum of 2 to 2.5 g daily in 2 to 3 divided doses. If targets not achieved with metformin alone, insulin may be added (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28077460','lexi-content-ref-23068960','lexi-content-ref-18463376','lexi-content-ref-23020608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28077460','lexi-content-ref-23068960','lexi-content-ref-18463376','lexi-content-ref-23020608'])">Ref</a></span>). <b>Note:</b> Insulin is the preferred medication for gestational diabetes as it does not cross the placenta to a measurable extent; all oral agents lack long-term safety data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7c6d30d-d483-4d0f-8771-219bea38bf59">Ovarian hyperstimulation syndrome prevention in patients with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian hyperstimulation syndrome prevention in patients with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection (alternative agent) (off-label use</b>
<b>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use prior to and/or during ovarian stimulation in patients undergoing a gonadotropin-releasing hormone agonist protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30033227','lexi-content-ref-33347618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30033227','lexi-content-ref-33347618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 500 mg once daily; increase dose gradually as tolerated up to 2 g/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21606131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21606131'])">Ref</a></span>). Dosage range studied in trials: 1 to 2.55 g/day in 2 or 3 divided doses; use of ER products may reduce GI adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16785142','lexi-content-ref-21982727','lexi-content-ref-23194199','lexi-content-ref-16501038','lexi-content-ref-30033227','lexi-content-ref-33347618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16785142','lexi-content-ref-21982727','lexi-content-ref-23194199','lexi-content-ref-16501038','lexi-content-ref-30033227','lexi-content-ref-33347618'])">Ref</a></span>). Discontinue metformin with a positive pregnancy test (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30033227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30033227'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Metformin conversion recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conversion from IR to ER dosage forms:</i> Patients receiving metformin immediate-release may be switched to metformin extended-release once daily at the same total daily dose, up to 2 g once daily. However, in patients who are doing well with immediate-release metformin, some experts recommend they continue using it, as there is little additional benefit documented with ER tablets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991520"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary. Monitor renal function at least annually.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;45 to &lt;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary. Metformin plasma concentrations may be higher compared to patients with an eGFR ≥60 mL/minute/1.73 m<sup>2</sup>; increase monitoring of renal function (eg, every 3 to 6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21617112','lexi-content-ref-32998798','lexi-content-ref-29305402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21617112','lexi-content-ref-32998798','lexi-content-ref-29305402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to 45 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initiation of therapy:</i> Use generally not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Manu.1'])">Ref</a></span>); however, initial therapy with 500 mg once daily with the evening meal titrated to 500 mg twice daily, if tolerated, with close monitoring of kidney function has been recommended by some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29305402','lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29305402','lexi-content-ref-Wexler.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuation of existing therapy:</i> May continue at a reduced dose up to a maximum of 500 mg twice daily with close monitoring of kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21617112','lexi-content-ref-25536258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21617112','lexi-content-ref-25536258'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney injury during therapy: </b>If acute kidney injury occurs or if risk factors are present (eg, severe vomiting or diarrhea), instruct patient to temporarily hold metformin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Diabetes.1','lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Diabetes.1','lexi-content-ref-Wexler.2'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988900"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: Key pharmacokinetic changes in hepatic insufficiency:</b> Metformin is not metabolized by the liver and is primarily eliminated unchanged by the kidney. The liver is the primary site of lactic acid metabolism and lactic acid–producing events<i>,</i> such as active alcohol consumption, dehydration, hypotension, sepsis, reduced cardiac function, or reduced kidney function, may enhance accumulation of lactic acid. Metformin increases lactic acid production in a dose-dependent manner and may result in overt lactic acidosis when coupled with liver dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35074477','lexi-content-ref-28736433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35074477','lexi-content-ref-28736433'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial or dose titration in patients with preexisting liver cirrhosis: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In patients with concurrent kidney impairment, eGFR ≤45 mL/minute/1.73 m<sup>2 </sup>and Child-Turcotte-Pugh A or B, defer to dosing in altered kidney function in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34401527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34401527'])">Ref</a></span>). Monitor kidney function frequently (eg, every 1 to 3 months) (expert opinion) during continuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172646','lexi-content-ref-34401527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172646','lexi-content-ref-34401527'])">Ref</a></span>)<i>.</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class A</b>
<b>
<i>: </i></b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-31960986','lexi-content-ref-29330714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-31960986','lexi-content-ref-29330714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class B</b>
<b>: </b>500 mg once daily; may increase by ≤500 mg/day increments every 30 days based on tolerability and response (expert opinion); consider slower titration (eg, every 60 days) in patients on concurrent agents that cause diarrhea (eg, lactulose) or fluid loss (eg, diuretics) (expert opinion); maximum dose: 1.5 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28459036','lexi-content-ref-35317103','lexi-content-ref-34198358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28459036','lexi-content-ref-35317103','lexi-content-ref-34198358'])">Ref</a></span>). <b>Note:</b> Do not initiate in patients at risk for lactic acid–producing events (eg, active alcohol consumption, dehydration, hypotension, sepsis, reduced cardiac function, reduced kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28459036','lexi-content-ref-35317103','lexi-content-ref-34198358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28459036','lexi-content-ref-35317103','lexi-content-ref-34198358'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class C</b>: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35317103','lexi-content-ref-34198358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35317103','lexi-content-ref-34198358'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with concurrent kidney impairment, eGFR ≤45 mL/minute/1.73 m<sup>2 </sup>and Child-Turcotte-Pugh A or B, defer to dosing in altered kidney function in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34401527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34401527'])">Ref</a></span>). Monitor kidney function frequently (eg, every 1 to 3 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>) during continuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172646','lexi-content-ref-34401527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172646','lexi-content-ref-34401527'])">Ref</a></span>)<i>.</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-31960986','lexi-content-ref-29330714','lexi-content-ref-24798175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-31960986','lexi-content-ref-29330714','lexi-content-ref-24798175'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from Child-Turcotte-Pugh class A to B: </b>No dosage adjustment necessary; however, a dose reduction may be required in patients at risk for lactic acid–producing events (eg, active alcohol consumption, dehydration, hypotension, sepsis, reduced cardiac function, reduced kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-29330714','lexi-content-ref-24798175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-29330714','lexi-content-ref-24798175'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Progression from Child-Turcotte-Pugh class B to C:</b> If tolerating with appropriate clinical endpoints, use with caution; discontinue metformin therapy in patients at risk for or who experienced a lactic acid–producing event (eg, active alcohol consumption, dehydration, hypotension, sepsis, reduced cardiac function, reduced kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-29330714','lexi-content-ref-34198358','lexi-content-ref-34401527','lexi-content-ref-24798175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-29330714','lexi-content-ref-34198358','lexi-content-ref-34401527','lexi-content-ref-24798175'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute hepatotoxicity during treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute worsening of hepatic function (eg, requiring hospitalization): </b>Discontinue metformin during the acute event (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>). Once the acute event has resolved, may resume metformin at pre-event doses (expert opinion). Permanent discontinuation should be considered for patients who recently experienced lactic acidosis, are at high risk of recurrent decompensation, or at risk of lactic acid–producing events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-29330714','lexi-content-ref-34198358','lexi-content-ref-34401527','lexi-content-ref-24798175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172646','lexi-content-ref-Erasmus.1','lexi-content-ref-35317103','lexi-content-ref-29330714','lexi-content-ref-34198358','lexi-content-ref-34401527','lexi-content-ref-24798175'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Metformin-induced hepatotoxicity:</b> Permanently discontinue metformin therapy. Although metformin is not metabolized by the liver, rare cases of metformin-induced hepatotoxicity have been reported within weeks of initiation, but concurrent use of other hepatotoxic medications is common. Most patients present with jaundice, fatigue, and elevated AST/ALT. Upon discontinuation of metformin, LFTs normalize over days to weeks and reoccurs upon rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9626034','lexi-content-ref-22679227','lexi-content-ref-24263160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9626034','lexi-content-ref-22679227','lexi-content-ref-24263160'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54311968"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Transient and/or reversible gastrointestinal (GI) adverse reactions, including <b>diarrhea</b>, <b>nausea</b>, <b>flatulence</b>, <b>dyspepsia</b>, <b>vomiting</b>, and <b>abdominal pain</b>, among others, are the most commonly reported adverse reactions with metformin use; intolerance to these reactions is often a reason for discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27987248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27987248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; mechanism not fully understood. Multiple mechanisms have been proposed that may contribute, including alterations in transporters (eg, organic cation transporter 1 [OCT1]), direct serotoninergic-like effects, increased gut motility, direct or indirect increases in glucagon-like peptide 1 (GLP-1), and disruptions in bile (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27987248','lexi-content-ref-10651152','lexi-content-ref-25510240','lexi-content-ref-27493135','lexi-content-ref-26780750','lexi-content-ref-26335661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27987248','lexi-content-ref-10651152','lexi-content-ref-25510240','lexi-content-ref-27493135','lexi-content-ref-26780750','lexi-content-ref-26335661'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; typically occurs at initiation of therapy; however, late onset of diarrhea has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11714216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11714216'])">Ref</a></span>). GI adverse reactions generally subside after several weeks of therapy; however, some patients require discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose escalation</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of IR formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15119994','lexi-content-ref-36187122','lexi-content-ref-24658791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15119994','lexi-content-ref-36187122','lexi-content-ref-24658791'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic asymptomatic gastritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26032654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26032654'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• Helicobacter pylori</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25391019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25391019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of OCT1-inhibiting agents (eg, verapamil, proton pump inhibitors) may be a potential risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25510240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25510240'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Postmarketing cases of metformin-associated <b>lactic acidosis</b> (MALA) have resulted in hypothermia, hypotension, resistant bradyarrhythmias, and death. The onset is often subtle, accompanied by nonspecific symptoms (eg, malaise, myalgia, respiratory distress, somnolence, abdominal pain); elevated blood lactate levels (&gt;5 mmol/L); anion gap acidosis (without evidence of ketonuria or ketonemia); and/or increased lactate:pyruvate ratio. Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Safety data for use in advanced heart failure (stage D) is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; inhibition of mitochondrial electron transport, an effect that favors anaerobic metabolism and the accumulation of lactate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26773926','lexi-content-ref-23768030','lexi-content-ref-22568883']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26773926','lexi-content-ref-23768030','lexi-content-ref-22568883'])">Ref</a></span>), resulting in lactic acidosis without evidence of tissue hypoxia (type B lactic acidosis). In addition, if accumulation occurs (eg, in patients with kidney impairment) or if high doses are administered (eg, in overdose), glucose utilization decreases and hepatic production of lactate increases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16675650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16675650'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; may occur at any time during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i> In general, risk is increased with increased metformin concentration, decreased lactate clearance, and/or increased lactate production.</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment; risk increases with the severity of kidney impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatic impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Reduced tissue perfusion such as in unstable heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of certain drugs that impair kidney function, cause significant hemodynamic changes, interfere with acid-base balance, or increase metformin accumulation</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients ≥65 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• Radiologic study with contrast</p>
<p style="text-indent:-2em;margin-left:6em;">• Surgery and other procedures due to potential for volume depletion, hypotension, and kidney impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypoxic states (eg, acute heart failure, acute myocardial infarction, sepsis, shock)</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive alcohol intake</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vitamin B12 deficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of metformin has been associated with reversible <b>vitamin B<sub>12</sub> deficiency</b> and subsequent anemia and neuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900641','lexi-content-ref-37611751','lexi-content-ref-29174300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900641','lexi-content-ref-37611751','lexi-content-ref-29174300'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Time-related; long-term use metformin interferes with the absorption of vitamin B<sub>12</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2020'])">Ref</a></span>); potential mechanism includes interference of vitamin B<sub>12</sub>-intrinsic factor absorption in the terminal ileum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900641'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; occurs with chronic use of metformin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37611751','lexi-content-ref-36628003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37611751','lexi-content-ref-36628003'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Higher doses (eg, &gt;1,000 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36628003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36628003'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Inadequate B<sub>12</sub> stores, poor underlying nutrition, and inadequate calcium intake or absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2020','lexi-content-ref-26900641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2020','lexi-content-ref-26900641'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older patients (eg, &gt;65 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34308109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34308109'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F193824"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (IR tablet: 53%; ER tablet: 10%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, flatulence (12%)<span class="lexi-table-link-container"> (<a aria-label="Flatulence table link" class="lexi-table-link" data-table-id="lexi-content-flatulence" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-flatulence')">table 2</a>)</span><span class="table-link" style="display:none;">Flatulence</span>, nausea and vomiting (IR tablet: 26%; ER tablet: 7%)<span class="lexi-table-link-container"> (<a aria-label="Nausea and vomiting table link" class="lexi-table-link" data-table-id="lexi-content-nausea-and-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea-and-vomiting')">table 3</a>)</span><span class="table-link" style="display:none;">Nausea and vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Metformin: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">53%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to 2,550 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IR tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">141</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ER tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">781</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">195</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Flatulence" frame="border" id="lexi-content-flatulence" rules="all">
<caption style="text-align:center;">
<b>Metformin: Adverse Reaction: Flatulence</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to 2,550 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IR tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">141</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea and vomiting" frame="border" id="lexi-content-nausea-and-vomiting" rules="all">
<caption style="text-align:center;">
<b>Metformin: Adverse Reaction: Nausea and Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to 2,550 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IR tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">141</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ER tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">781</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">195</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, flushing, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, nail disease</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia, vitamin B<sub>12</sub> deficiency (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, abdominal distress (6%), abdominal pain, abnormal stools, dyspepsia (7%)<span class="lexi-table-link-container"> (<a aria-label="Dyspepsia table link" class="lexi-table-link" data-table-id="lexi-content-dyspepsia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyspepsia')">table 4</a>)</span><span class="table-link" style="display:none;">Dyspepsia</span>, heartburn</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyspepsia" frame="border" id="lexi-content-dyspepsia" rules="all">
<caption style="text-align:center;">
<b>Metformin: Adverse Reaction: Dyspepsia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Metformin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to 2,550 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IR tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">141</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (9%), chills, dizziness, headache (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, flu-like symptoms, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Fixed drug eruption (Ramírez-Bellver 2017; Steber 2016), lichen planus (Azzam 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Lactic acidosis (DeFronzo 2016; Eppenga 2014; Salpeter 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Damughalta 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (Packer 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (cholestatic, hepatocellular, and mixed) (Babich 1998; Nammour 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Voore 2016), hypersensitivity angiitis (Czarnowicki 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (Béjot 2015; Jung 2009; Kang 2013)</p></div>
<div class="block coi drugH1Div" id="F193840"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to metformin or any component of the formulation; severe renal dysfunction (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>); acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): End-stage renal disease, patients on dialysis, or when renal function is unknown; unstable and/or insulin-dependent (type 1) diabetes mellitus; history of ketoacidosis with or without coma; history of lactic acidosis (regardless of precipitating factors); excessive alcohol intake (acute or chronic); severe hepatic dysfunction or clinical or laboratory evidence of hepatic disease; patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials; cardiovascular collapse and disease states associated with hypoxemia, including cardiorespiratory insufficiency, which are often associated with hyperlactacidemia; stress conditions (eg, severe infection, trauma, surgery and postoperative recovery phase); severe dehydration; pregnancy; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F193821"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Altered absorption: Use of IR tablets or solution after surgery is generally preferred. ER tablets may have a reduced effect after gastric bypass or sleeve gastrectomy due to the direct bypass of the stomach and proximal small bowel with gastric bypass or a more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy (Mechanick 2020; Melissas 2013). After gastric bypass (Roux-en-Y gastric bypass [RYGB]), administration of IR tablets led to increased absorption (AUC<sub>0-</sub>
<sub>∞</sub> increased by 21%) and bioavailability (increased by 50%) (Padwal 2011). Lactate levels decrease after gastric bypass (RYGB)-induced weight loss irrespective of the use of metformin. Routinely lowering metformin dose after gastric bypass is not necessary as long as normal renal function is preserved (Deden 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Metformin may be used in patients with stable heart failure (ADA 2022). Use cautiously or avoid in hypoperfusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use cautiously in patients at risk for lactic acidosis (Brackett 2010; Crowley 2017; Zhang 2014). An increased risk of mortality has been observed with higher metformin doses (eg, &gt;1 g) and more severe liver dysfunction (eg, Child-Turcotte-Pugh C&gt;B&gt;&gt;&gt;A) (Yen 2022). Cases of metformin-induced hepatotoxicity have also been reported (LiverTox 2020; Zheng 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Metformin is substantially excreted by the kidney; dosing adjustments may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ER tablet: A soft mass resembling the tablet may appear in the stool.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>• </i>Appropriate use<i>: </i>Not indicated for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Iodinated contrast: Administration of iodinated contrast agents has been associated with postcontrast acute kidney injury (AKI); acute decreases in renal function have been associated with an increased risk of lactic acidosis due to reduced metformin excretion (ACR 2021; manufacturer’s labeling). Current guidelines recommend temporarily withholding metformin prior to or at the time of iodinated contrast administration in patients with known AKI or severe chronic kidney disease (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>), or who are undergoing arterial catheter studies (ACR 2021). Some experts also temporarily withhold metformin in patients with an eGFR &lt;45 mL/minute/1.73 m<sup>2</sup> or risk factors for lactic acidosis (eg, hypotension, vascular instability, potential hypoperfusion) (Rudnick 2021; Wexler 2021b). If metformin is withheld, reassess kidney function ≥48 hours after contrast administration and resume therapy if kidney function is acceptable (ACR 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical procedures: Metformin-containing products should be withheld the day of surgery; restart after renal function is stable (ADA 2022).</p></div>
<div class="block prod-avail drugH1Div" id="F56709724"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Riomet ER suspension has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F193832"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Riomet: 500 mg/5 mL (118 mL, 473 mL) [contains propylene glycol; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Riomet: 500 mg/5 mL (118 mL, 473 mL) [contains saccharin calcium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/5 mL (5 mL, 8.5 mL, 118 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Riomet ER: 500 mg/5 mL (480 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 625 mg, 850 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fortamet: 500 mg [DSC], 1000 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glumetza: 500 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 750 mg, 1000 mg</p></div>
<div class="block geq drugH1Div" id="F193817"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F193842"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (metFORMIN HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $2.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Riomet Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $1.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Glumetza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $61.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $133.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (metFORMIN HCl ER (MOD) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $8.40 - $55.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $16.67 - $120.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (metFORMIN HCl ER (OSM) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $4.52 - $17.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $6.38 - $31.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (metFORMIN HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.75 - $1.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $1.20 - $1.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (metFORMIN HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.26 - $1.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">625 mg (per each): $37.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">850 mg (per each): $0.07 - $1.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $0.08 - $2.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867486"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glucophage: 500 mg, 850 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glycon: 500 mg, 850 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 850 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glumetza: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glumetza: 1000 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 1000 mg</p></div>
<div class="block admp drugH1Div" id="F52613270"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with a meal (to decrease GI upset).</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Administer in divided doses with meals. Administer oral solution with supplied dosing cup.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Administer with evening meal. Shake well at least 10 seconds before use; use supplied dosing cup to measure dose. Rinse dosing cup with water only after each use to clean.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Administer once-daily doses with the evening meal; swallow whole; do not cut, crush, or chew.</p></div>
<div class="block adm drugH1Div" id="F193837"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with a meal (to decrease GI upset). Administer solution and suspension with supplied dosing cup.</p>
<p style="text-indent:-2em;margin-left:2em;">ER tablets: Swallow whole; do not crush, cut, or chew. Administer once-daily doses with the evening meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablets and oral solution formulations are available. If safety and efficacy of metformin ER formulations can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, avoidance of Glumetza may be advisable as this formulation is designed to be retained in the stomach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Glumetza.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Glumetza.3'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F193853"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral solution (immediate release): Store at 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension (extended release): Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F). Discard unused portion of reconstituted suspension after 100 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture.</p></div>
<div class="block usep drugH1Div" id="F53567752"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of type 2 diabetes mellitus when hyperglycemia cannot be managed with diet and exercise alone (Immediate release [tablets, oral solution]: FDA approved in ages ≥10 years and adults; extended release: Oral suspension [Riomet ER]: FDA approved in ages ≥10 years and adults; Tablets: FDA approved in adults); has also been used for weight loss in pediatric patients with severe obesity and insulin resistance in conjunction with a comprehensive lifestyle weight management program; treatment of weight-gain secondary to antitypical antipsychotic use.</p></div>
<div class="block mst drugH1Div" id="F193915"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MetFORMIN may be confused with metroNIDAZOLE</p>
<p style="text-indent:-2em;margin-left:4em;">Glucophage may be confused with Glucotrol, Glutofac</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dianben [Spain] may be confused with Diovan brand name for valsartan [US, Canada, and multiple international markets].</p>
<p style="text-indent:-2em;margin-left:4em;">Glucon brand name for metformin [Malaysia, Singapore] is also the brand name for glucosamine [Singapore]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299680"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F193826"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of MetFORMIN. Specifically, excessive alcohol ingestion (acute or chronic) may potentiate the risk of lactic acidosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to this combination or use of lower metformin doses. Carefully weigh the risk of metformin toxicities (including lactic acidosis) against the benefit of combining dolutegravir with metformin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with MATE1/2-K substrates when possible. If combined, monitor for increased MATE1/2-K substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with OCT2 substrates when possible. If combined, monitor for increased OCT2 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fludeoxyglucose F 18: MetFORMIN may diminish the diagnostic effect of Fludeoxyglucose F 18.  Management: Consider holding metformin for 48 hours or longer prior to PET scans using fludeoxyglucose F18 (FDG-F18) when imaging of the colon or intestine is required. Consider increased monitoring of blood glucose when metformin is held.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guar Gum (Partially Hydrolyzed): May decrease the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MATE1/2-K Inhibitors: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylol Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, and Ritonavir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of MetFORMIN. Management: Administer metformin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May increase the serum concentration of MetFORMIN. Management: Limit the metformin dose to a maximum of 1,700 mg per day when used together with ranolazine 1,000 mg twice daily. Monitor patients for metformin toxicities, including lactic acidosis and carefully weigh the risks and benefits of this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased. MetFORMIN may increase the serum concentration of Topiramate. Topiramate may increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May diminish the therapeutic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): MetFORMIN may diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F193854"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases the extent and slightly delays the absorption. Management: Administer with a meal.</p></div>
<div class="block dic drugH1Div" id="F193845"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Drug may cause GI upset; take with food (to decrease GI upset). Take at the same time(s) each day. Dietary modification based on ADA recommendations is a part of therapy.</p></div>
<div class="block rep_considerations drugH1Div" id="F49297896"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Metformin is approved for the treatment of type 2 diabetes mellitus; however, it is not preferred for use if pregnancy should occur. Regardless of treatment, patients with diabetes who could become pregnant should use effective contraception and those planning to become pregnant should continue contraception until glycemic control is achieved. When diet and exercise alone are not enough for the treatment of type 2 diabetes mellitus, metformin may be continued in select patients who are well controlled prior to pregnancy, such as those who are unwilling or unable to use insulin (ACOG 2018; ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Metformin has been studied in patients with polycystic ovarian syndrome (PCOS) who have reproductive symptoms such as irregular menstrual cycles and infertility.</p>
<p style="text-indent:-2em;margin-left:4em;">• Adjunctive use of metformin may improve metabolic features of PCOS in patients when combination oral contraceptives and lifestyle modifications are not effective. Metformin may be most effective for patients with diabetes risk factors, impaired glucose tolerance, or a BMI ≥25 kg/m<sup>2</sup> (Teede 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Metformin (in combination with clomiphene) may be considered for ovulation induction in patients diagnosed with PCOS and anovulatory infertility (and no other infertility factors), who have a BMI ≥30 kg/m<sup>2</sup>, and who wish to conceive. Pregnancy should be excluded prior to treatment (Teede 2018). Metformin monotherapy is no longer recommended for routine use for ovulation induction in patients with PCOS and anovulatory infertility but may be considered in patients who are unable or unwilling to take more effective agents (ASRM 2017; Teede 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Adjunctive use of metformin may reduce the risk of ovarian hyperstimulation syndrome (OHSS) and improve pregnancy rate in patients with PCOS and anovulatory infertility who are undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Metformin should be discontinued once there is a positive pregnancy test unless it is needed for another indication (Teede 2018).</p></div>
<div class="block pri drugH1Div" id="F193843"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Metformin crosses the placenta; concentrations may be comparable to or higher than those found in the maternal plasma (ADA 2022; Charles 2006; de Oliveira Baraldi 2011; Eyal 2010; Vanky 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following first trimester exposure from paternal (Wensink 2022) and maternal (Cao 2021; Cassina 2014; Gilbert 2006; Panchaud 2018; Scherneck 2018; Zeng 2016) use of metformin are available. Maternal and fetal/neonatal outcomes are influenced by underlying maternal disease (eg, gestational diabetes mellitus [GDM] or polycystic ovary syndrome [PCOS]) (Cao 2021; Panchaud 2018; Zeng 2016). An increased risk of birth defects or adverse fetal/neonatal outcomes has not been observed following maternal use of metformin for gestational diabetes mellitus or type 2 diabetes mellitus when glycemic control is maintained (Balani 2009; Coetzee 1984; Ekpebegh 2007; Niromanesh 2012; Rowan 2008; Rowan 2010; Tertti 2008). Studies which evaluated children up to 12 years of age with previous in utero exposure to metformin have shown conflicting outcomes related to BMI and other growth parameters; however, results may be confounded by underlying maternal disease (eg, GDM, PCOS) and concomitant therapy (eg, insulin) (ADA 2022; Brand 2022; Paavilainen 2022; Skibinska 2021). Additional long-term data are needed (ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of metformin may be altered. Changes in renal blood flow alter renal clearance; in one study this significantly decreased plasma concentrations of metformin for pregnant patients taking a dose of 1 g/day but not doses of 2 g/day. Changes in renal clearance correlated with changes in creatinine clearance (Eyal 2010; Liao 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy is associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than metformin are currently recommended to treat diabetes mellitus in during pregnancy (ADA 2022). Metformin may be considered for the treatment of GDM in patients who cannot safely or effectively use insulin (eg, due to cost, language barriers, comprehension, cultural issues). However, metformin monotherapy fails to provide adequate glycemic control in all patients. Metformin should not be used in patients with hypertension, preeclampsia, or those at risk for intrauterine growth restriction due to risk of fetal growth restriction or acidosis in the setting of placental restriction. Metformin is not the preferred treatment of type 2 diabetes mellitus during pregnancy (ADA 2022). Metformin, in addition to insulin, may be considered for some pregnant patients with type 2 diabetes mellitus due to potential maternal and neonatal benefits (eg, reduced insulin requirements, less maternal weight gain, fewer caesarean births, reduced incidence of macrosomia), although additional long-term data are needed (Benham 2021; Feig 2020).</p>
<p style="text-indent:0em;margin-top:2em;">PCOS is also associated with adverse pregnancy outcomes, including an increased risk of GDM, miscarriage, pregnancy-induced hypertension, preeclampsia, and preterm delivery. When used in the management of PCOS, metformin may reduce the risk of preterm delivery; however, the incidence of GDM, miscarriage, or preeclampsia are not affected (Cao 2021). Metformin monotherapy has not been found to improve the live birth rate in patients with PCOS when used for ovulation induction or in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) (Magzoub 2022; Tso 2020; Wu 2020). If metformin is used for ovulation induction in patients with PCOS, treatment should be discontinued by the end of the first trimester (ADA 2022). In patients undergoing IVF/ICSI, metformin should be discontinued once there is a positive pregnancy test unless it is needed for another indication (Teede 2018).</p></div>
<div class="block mopp drugH1Div" id="F53567749"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors; some patients may be candidates for continuous glucose monitoring) (ADA 2023); electrolytes; renal function (at diagnosis and at least annually); hepatic function, hematologic parameters (annually), vitamin B<sub>12</sub> serum concentrations (every 2 to 3 years); folate (if megaloblastic anemia is suspected) (manufacturer's labeling). Monitor weight, height (or length if &lt;24 months), and BMI every 3 months in pediatric patients &lt;7 years with type 1 diabetes (ISPAD [Sundberg 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">HbA<sub>1c</sub>: Monitor every 3 months; some recommendations suggest at least twice yearly may be considered in patients who have stable glycemic control and are meeting treatment goals (ADA 2023; ISPAD [de Bock 2022]; ISPAD [Shah 2022]). <b>Note:</b> In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rerp drugH1Div" id="F53567609"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Patients with Diabetes: Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus or pump regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the "peak."</p>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Blood glucose:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Type 2 diabetes:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Fasting plasma glucose: 70 to 110 mg/dL (SI: 3.9 to 6.1 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">Postprandial glucose: 70 to 140 mg/dL (SI: 3.9 to 7.8 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia and is reasonable in many patients with type 2 diabetes; less aggressive goals (&lt;7.5%) may be appropriate in patients who are at increased risk of hypoglycemia (ADA 2023; ISPAD [de Bock 2022]; ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical patients (ISPAD [Kapellen 2022]):</p>
<p style="text-indent:-2em;margin-left:6em;">Intraoperative: 90 to 180 mg/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">ICU, postsurgery: 140 to 180 mg/dL.</p></div>
<div class="block pha drugH1Div" id="F193820"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)</p></div>
<div class="block phk drugH1Div" id="F193839"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within days; maximum effects up to 2 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 654 ± 358 L; partitions into erythrocytes; concentrates in liver, kidney, and GI tract.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Negligible.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized by the liver.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Absolute: Fasting: 50% to 60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Plasma: 4 to 9 hours; Blood ~17.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Immediate release: 2 to 3 hours; ER tablet: 6 to 8 hours; ER suspension: 4.5 hours (range: 3.5 to 6.5 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (90% as unchanged drug; active secretion).</p></div>
<div class="block phksp drugH1Div" id="F51159464"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Peak and systemic exposure is increased, and oral and renal clearance is decreased.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Obesity: In 22 pediatric patients who were obese (mean age: 14.5 ± 1.8 years; range: 11.1 to 17.5 years), pharmacokinetic analysis showed that clearance significantly increases and AUC decreases with increasing total body weight (van Rongen 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Total plasma clearance is decreased, half-life is prolonged, and C<sub>max</sub> is increased.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F193846"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dialon | Diaphage | Formit xr | Glenphage | Glucophage | Glucormin xr | Gluformin xl | Gluventa xr | Melmet | Metaphage | Metfor | Omformin | Pivox | Xmet sr</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Baligluc AP | D.B.I. AP Metformina | D.B.I. Metformina | Dazomet | Dbi ap | Dbi ap forte | Dbi metformina | Diab dos | Diabesil | Diabesil ap | Duburina | Glicenex | Glicenex sr | Glucaminol | Glucogood | Glucophage | Glucophage xr | Glumet | Hipoglucin | Imecot | Imecot ap | Imecot forte | Islotin | Mectin | Medobis | Metforal | Metformin Temis | Metformina | Metformina Hlb | Metformina iraola | Metformina northia | Metformina puntanos | Metformina sandoz | Metformina Vannier | Metglucon | Metglucon AP | Mtf | Nogluc | Quexel | Redugluc | Redugluc a.p.</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Arcamet | Desugar | Diabetex | Diabetormin | Glucophage | Meglucon | Metformin | Metformin 1a pharma gmbh | Metformin arcana | Metformin bluefish | Metformin Genericon | Metformin germania pharm | Metformin hexal pharma | Metformin Pfizer | Metformin sandoz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo metformin | Apo metformin xr | Apotex metformin | Apx metformin | Auro metformin | Chemmart metformin | Chemmart metformin xr | Cip metformin | Cipla genpharm metformin hydrochloride | Cipla metformin | Cm metformin | Diabex | Diaformin | Diaformin xr | Diaxemet xr | Emnorm | Fetmin xr | Formet | Genrx metformin xr | Glucobete | Glucohexal | Glucomet | Glucophage | Glucophage xr | Gta metformin | Ipca metformin | Lyomet xr | M formin xr | Medformin | Meditab metformin | Metcip | Metex xr | Metformin | Metformin alphapharm | Metformin an | Metformin arrow xr | Metformin arw xr | Metformin arx | Metformin ch | Metformin ch xr | Metformin Ga | Metformin Generic Health | Metformin genpar xr | Metformin gh | Metformin gh xr | Metformin gppl xr | Metformin gxp xr | Metformin Pfizer | Metformin Ranbaxy | Metformin sandoz | Metformin str | Metformin xr apotex | Metformin-bc | Metmin | Metofex xr | Noumed metformin | Novomet | Pharmacor metformin xr | Pip metformin | Ptin metformin | Terry white chemists metformin | Tn metformin | Tw Metformin | Yaltormin sr</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Bigmet | Comet | Comet xr | Daomin | Diabex | Diablo | Diafree | Diamet | Dimet | Diout | Etform | Exformin | Formet | Glucomet | Glucomin | Glucophage | Gluphage | Glymin | Guamin | Informet | Insimet | M min | Mefin | Meforex | Meforin | Meformin | Meglu | Met | Metabex | Metfar | Metfen | Metfo | Metforal | Metform | Metlife | Metmin | Metnil | Metomin | Metsa | Nobesit | Nvmet | Obemet | Onmet | Oramet | Ormin | Polimet | Preform | Radimet | SB Met | SB Met XR | Sucomet | Sugamet | Xelmet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docmetformi | Glucophage | Metformax | Metformin Pfizer | Metformine bexal | Metformine merck-generics | Metformine Sandoz | Metformine teva generics belgium | Vale Metformin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Fairmet | Glucophage | Metforal | Metformin denk | Metformin zentiva | Metformine | Ranophage</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Brotmin | Glucophage | Glucophage xr | Meglucon | Metfocon | Metfodiab | Metfogamma | Metformin | Metformin ecopharm | Metformin Nihfi | Normaglyc | Siofor | Siofor SR | Sophamet</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Clor Metformina | Cloridrato de metformina | Clororidrato de metformina | Diaformin | Dimefor | Formet | Formyn | Glicefor | Glicomet | Glifage | Glifage xr | Gliformil | Glucoformin | Hipoformin | Meguanin | Metfordin | Metforgen | Metform | Metformed | Metta | Mytfor | Neo metformin | Teutoformin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gluconormin | Glucophage | Metfin | Metformin 1a pharma | Metformin actavis | Metformin axapharm | Metformin Helvepharm | Metformin sandoz | Metformin Spirig HC | Metformin zentiva | Metformin-Mepha</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Auro metformin | Diaformine | Diamin | Dimet | Emnorm | Metafor | Metclass | Metfil | Metfo | Metforal | Metform | Metformin denk | Metformine | Metformine zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Andibet | Diaglitab | Dimefor | Fintaxim | Glafornil | Glaupax 1000 xr | Glaupax 500 xr | Glaupax 750 xr | Glicenex | Glicex | Glicosol | Glicosol xr | Glidanil | Glifortex | Glimefor | Glimefor xr | Glucophage | Glucophage forte | Glucophage xr | Glucosan | Hipoglucin | Metformina | Metforvitae | Oxemet | Salidiab | Tavist xr</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei shun | Bo ke | De ai xin | Diaformin | Dou le ning | Fu xing tian ming | Glucophage | Glucophage xr | Ji ji | Jiang li shu | Jin zhen xing | Jun shi da | Jun shi da xin | Li ke tang | Li le er | Mai ke luo xin | Mai te mei | Mei di kang | Metformin | Metformin hydrochloride sustained release tablets (ii) | Qing kuang | Rui jiu | Rui nuo shu | Shuang le xin | Tai bai | Tang bi fu | Yan suan er jia shuang gua | Yi heng | Yue da ning | Zhong shi de</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Biguax | Clorhidrato de metformina | Diclufor | Diglufor | Dimefor | Emnorm er | Exelmet | G-met | Gliformin | Glisyn | Glucaminol | Glucophage | Mefox | Metforex | Metformin | Metformina | Metformina clorhidrato | Metformina denk | Metgluk | Metsafe | Metsulina | Predial Lex | Quexel</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">Diaberim</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adimet | Apo metformin | Brotmin | Diaphage | Diareg | Diformin | Glucomerck | Glucophage | Gluformin | Metfirex | Metfogamma | Metformin | Metformin al | Metformin aurovitas | Metformin bluefish | Metformin mylan | Metformin vitabalans | Mulado | Normaglyc | Siofor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aranka | Biocos | Bonformin | Diabesin | Diabetase | Espa formin | Glucobon | Glucophage | Juformin | Mediabet | Meglucon | Mescorit | Met | Metfin | Metfodoc | Metfogamma | MetfoLiquid GeriaSan | Metfor | Metform | Metformin | Metformin accedo | Metformin al | Metformin aps | Metformin Atid | Metformin aurobindo | Metformin axcount | Metformin biomo | Metformin bluefish | Metformin denk | Metformin dura | Metformin glenmark | Metformin Heumann | Metformin hexal | Metformin lich | Metformin N | Metformin Pfizer | Metformin r.a.n. | Metformin Ratiopharm | Metformin stada | Metformin-CT | Metformin-Puren | Metformine Volkspharma | Metforminhydrochlorid | Metkar | Metnit | Metsop | MetSurrir | Mettas | Metwan | Siofor | Siofor xr | Thiabet</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Asendia | Bexanel | Biguanil | Biguanil ap | Diaformina lp | Diamenil | Euromet | Feximet xr | Forchem | Forvel | Glidara | Glifort sr | Glisulin | Glubetic | Glucoless xr | Glucophage | Glucox XR | Mediabet | Mediabet sr | Meformax | Met Core | Metfcard 1000 | Metfcard 500 | Metfcard 850 | Metfonida | Metforal | Metformina | Metformina Exels | Metformina Feltrex | Metformina if | Metformina lam | Metformina Lam XR | Metformina MK | Metpiril | Predial plus | Proinsul | Zomet</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Biguanil | Clorhidrato de metformina | Diaformina | Ficonax | Glicenex | Gliformin | Glucaminol | Glucocid | Glucofage | Gluquinal | Hipoglucin | Libraformin | Metforal | Metformina | Metformina BKF | Metformina Medley | Metformina Nifa | Metformina sandoz | Metformina Winthrop | Metgluk | Metmida | Quexel | Repomet</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Glucophage | Gluformin | Metforal | Metforem | Metformin | Metformin Ratiopharm | Metformin sandoz | Metformin teva | Metformin vitabalans | Metformin zentiva | Metforminum | Orabet</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alexodiab | Amophage | Andoglycemic | Cidophage | Diaformin | Diaphage | Glucoformin | Glucolight | Glucophage | Maxophage xr | Meglucon | Mepaphage | Mepaphage SR | Metformin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Brotmin | Dianben | Metformina actavis | Metformina adler apotheke | Metformina almus | Metformina Apotex | Metformina aurobindo | Metformina Bluefis | Metformina Combix | Metformina Edigen | Metformina Kern Pharma | Metformina Mylan | Metformina mylan pharmaceuticals | Metformina normon | Metformina pensa pharma | Metformina pharmacia | Metformina pharmakern | Metformina Placasod | Metformina qualigen | Metformina RATIOPHARM | Metformina sandoz | Metformina tarbis | Metformina Teva | Ubene</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Brot | Diabetmin | Diamet | Diaphage | Glucophage | Glyformin | M forlin | Metformin | Metformin denk | Metformin HCL | Neomet</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Diformin | Glucophage | Metforem | Metformin actavis | Metformin alpharma | Metformin mylan | Metformin Pfizer | Metformin sandoz | Metformin teva | Metformin vitabalans | Oramet</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Diabamyl | Glucinan | Glucophage | Glymax | Meldaspin | Metfirex | Metformine | Metformine Almus | Metformine arrow | Metformine bgr | Metformine Biogaran | Metformine Bluefish | Metformine Cristers | Metformine evolupharm | Metformine g gam | Metformine gnr | Metformine irex | Metformine ivax | Metformine merck | Metformine Pfizer | Metformine phr | Metformine Qualimed | Metformine Ratiopharm | Metformine RPG | Metformine Sandoz | Metformine teva | Stagid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Axpinet | Bolamyn | Diagemet XL | Duformin | Glucamet | Glucient | Glucophage | Metabet | Metabet sr | Metformin | Metformin A L | Metformin almus | Metformin Arrow | Metformin astec | Metformin Berk | Metformin colonis | Metformin cox | Metformin DC | Metformin hydrochloride brown &amp; burk | Metformin Ivax | Metformin Kent | Metformin Kkb | Metformin Pfizer | Metformin rona | Metformin sandoz | Metformin teva | Metformin Wyeth | Metformin Zanza | Metiguanide | Metuxtan sr | Sukkarto | Yaltormin sr</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Bg met | Enaphage | Guamet</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Glucoformin | Glucofree | Glucophage | Glucoplus Gener | Glycofren | Lycis | Metformin actavis | Metformin/generics | Metformin/mylan | Sukontrol | Tiglor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo metformin | Apt Metformin | Auromet | Bf-Metformin | Bigmet | Cp-Metform | Diabetmin | Diabetmin xr | Diaformin | Glucodown | Glucofit | Glucomin | Glucophage | Gluformin | Glumet | Insufor | Melbin | Metformin | Metformin bdc | Metformin denk | Metformin stella | Metoformin | Metphar xr | Poliformin | Risidon | Volv</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aglurab | Belformin | Glucophage | Glucophage xr | Gluformin | Meglucon | Metformin PharmaS | Siofor</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adimet | Adimet xr | Glucophage la | Maformin | Meforal | Meglukon | Merckformin | Metfogamma | Metformin 1a pharma | Metformin actavis | Metformin bluefish | Metformin Chinoin | Metformin mylan | Metformin vitabalans | Metrivin | Mylmet</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adecco | Benofomin | Diabex | Diabit | Diafac | Diaformin | Eraphage | Forbetes | Fordica 500 xr | Formell | Gliformin | Glikos | Glucophage | Glucotika | Gludepatic | Glufor | Glumin | Glunor | Heskopaq | Metformin | Methpica | Metphar xr | Neodipar | Reglus | Reglus 500 | Tudiab | Zumamet</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Glucophage | Metformin | Metformin aurobindo | Metformin bluefish | METFORMIN Bluefish | Metformin pinewood | Metophage</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apophage | Glucomin | Glucophage | Glufor | Metformin teva</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Almetin | Ameto | Asugar | Baymet | Biciphage | Bidiab | Bigesens | Bigomet | Bigsens | Bigua SR | Bymet | Carbophage | Cetapin | Cetapin xr | Conformin sr | D-met | Daomet | Diafer | Diafer ER | Diaformin | Diagraf | Diamet | Diaten m | Dibeta sr | Dibeta TR | Dibimet | Diform | Dior | Dmbest SR | Elcephase | Emfor | Emnorm | Endoformin | Etformin | Evizen | Exermet | Formet | Formin | Forminal | Forson | G-met | G-reg | Gliz | Glorimet | Glucomate xr | Gluconorm | Gluformin | Gluformin xl | Glumet | Glup sr | Glupress | Glutamet | Glybza | Glyciphage | Glycomet | Glyrep | Hermtf | Incontrol | Instamet | Insumet | Ismet 500 | Ismet sr 500 | K-met | M forlin | Maxformin | Medfor | Medformin | Mefomin | Meftrol | Melmet | Mesite | Met 500 | Metabest | Metaday | Metadoze IPR | Metafor | Metafort | Metanorm | Metaphage-sr | Metasens | Metatime | Metbay | Metchek | Metcom | Metdiab | Metfil | Metfodil | Metfor | Metforise | Metgem | Metica | Metjet sr | Metkin | Metlead | Metlong | Metmin | Metmore | Metneed | MetNyle | Metol | Metol od | Metsafe | Metsar | Metsig | Metsmall | Metsurge | Metswift | Mf | Midamet | N-met | Natformin | Obimet | Okamet | Ozomet | Performin | Prime | Psymet | Redumet | Riomet | Roftem sr | Scodia | Serformin | Sugamet | Terformin | Walaphage | Winixia | Winsulin | Xmet | Zetfor | Zomet</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Glucomet | Metformin awa | Metphage | Piophage</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Glucophage | Glucophage unidie | Metbay | Metfonorm | Metforal | Metforalmille | Metformina | Metformina actavis | Metformina almus | Metformina aurobindo | Metformina Awp | Metformina blu | Metformina Doc | Metformina Myl | Metformina pharmacare | Metformina Pns | Metformina sandoz | Metiguanide | Slowmet | Zuglimet</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Brot | Dialon | Diamet | Diaphage | Formit | Glucare xr | Glucophage | Glucophage xr | Glyformin | Glymet | Meforin | Metforal | Mystro | Rivomet</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Diabetosu b | Glycoran | Insuloid m | Medet | Melbin | Metformin hcl pfizer | Metformin hydrochloride mt | Metformin organon | Metgluco | Metolmin | Metrion | Nelbis | Rhythmes</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asformin | Atformin | Bigomet | Biomet | Comet | Diabetmin | Dialon xr | Diamet | Diamin | Diaphage | Diaphage sr | Emformin | Exermet | Flomet | Forminal xr | Glucend | Glucodeal | Glucomet | Glucomet xr | Glucophage | Glucophage xr | Glucostat | Gludown | Glyciphage | Glyferon | Glyformin | Guamet | Lipimet | Lofin sr | Melmet 1000 sr | Melmet 500 sr | Metaday | Metchek | Metfil | Metfocip 1g sr od | Metforal | Metformin | Metformin denk | Metica | Metlong | Metmin | Metphage | Metswift | Metta | Mformin | Neomet | Neomet xr | Panfor sr | Ranophage od | Xmet</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A formin SR | Afomin | Apomin | Ausformin | Daibis | Daiformin | Daiformin er | Daimit | Diabex | Diabex xr | Diabic er | Diaformin | Diaformin xr | Diamet | Diamin | Diamin xr | Diaphage | Diformin | Diformin sr | Dimafolmin | Dimaformin sr | Dipomin | Dongsung metformin hcl | Dongwha metformin xr | Dybis | Dymit XR | Dynarb | Dynarb er | Emtfomin | Glavis | Glavis xr | Glinpegy | Glireb xr | Glirep | Gloformin | Gloforminm sr | Glu a | Glu m | Gluberin | Glucamin | Glucera | Glucera xr | Glucodown | Glucodown or | Glucogen | Gluconil | Glucophage | Glucophage xr | Glufamin | Gluformin | Glumeformin | Glumet | Glumetformin | Glupa | Glupermin | Glutamin | Glycomin | Glycomin sr | Greenphage | Hd metformine hcl | Hutmin | Il-yang metfor er | Inno.n metformin xr | Jeiformin | M formin | Mackpomin | Mefodin | Mefomin | Mefomin sr | Meformin | Megaformin | Megaformin sr | Melformin | Melformin sr | Mephage | Mepolin | Mepoline | Meponin | Meromin | Metapol | Metfamin | Metfo xr | Metfodid sr | Metfolem | Metfor | Metfor xr | Metfore m | Metformin | Metformin HCL | Metformin hcl koreaunited | Metformin sr | Metformin xr | Metfox Xr | Metglu sr | Metgreen Sr | Metmin | Metofol | Metofor | Metomin | Metone sr | Metophage xr | Metopol | Metormin | Metrenin | Metrin | Metro | Metromin | Metromin sr | Mformin | N fomin sr | Newmet | Nexformin xr | Nextformin | Novamet gr | Novotin | Novotin sr | Pharma metformin hcl | Pharvis metformin | Samik metformin | Samjin metformin | Teva metformin | Wonformin | Youngil metformin | Yuhan metformin hcl | Yuhan metformin xr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dialon | Dimet | Formit xr | Glucomet | Glucophage | Metaphage | Metfor | Neomet | Siofor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bigwin | Brot | Dianorm xr | Diaphage | Dimet | Gliafor | Glucophage | Gluforin XR | Glyformine | Glymet | Glystor | Met forte | Metformine | Neomid | Siofor | Stagid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Brotmin | Diformin | Glucophage | Glycomet | Metfogamma | Metforal | Metformin | Metformin bp | Metformin ingen | Metformin Ratiopharm | Metformin teva | Metformin vitabalans | Metformin Worwag | Metformin zentiva | Metforminhexal | Orabet | Siofor</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Glucophage | Metformax | Metformine Sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Brotmin | Diformin | Formetic | Glucophage | Gluformin | Metfogamma | Metforal | Metformin | Metformin aurobindo | Metformin Ratiopharm | Metformin sandoz | Metformin teva | Metformin zentiva | Orabet | Stadamet</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acol | Ado | Biguan | Diaformine | Glucophage | Glycan | Metformine Win | Stagid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Akspri | Amifor | Anglucid | Apozemia | Atenglus | Azugralex | Azugralex XR | Bigsens | Biodid | Dabex | Debeone d.t. nf | Debeone nf | Dimefor | Dimefor xr | Dinamel | Dinorax | Ficonax | Formidal | Glikovac | Glucibetina T | Glucogen | Glucophage | Glucophage xr | Glucotec s | Glunovag | Harbamind | Idyatyl | Ifor | Meglubet | Melbexa | Metformina | Metformina gi | Metformina gi serr | Metformina silanes | Metixor | Minraam | Nublast er | Pharmafet | Pharmafet lb | Pre-dial | Predial | Predial plus | Robergen | Setebaid | Sibet | Sirza | Zaprir | Zemoday</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ansures | Brot | Diabemet | Diabesafe | Diabetmin | Diabetmin retard | Diabetmin xr | Formet | Formin | Glucomet | Glucophage | Glucophage xr | Glucoxit | Glumet | Glumet D.C | Glumet xr | Glycomet | Metchek | Metformin | Metformin Pharmaniaga | Metformin stada | Metformin stella | Metkline | Metta | Oralmet | Proglutrol | Riomet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Afrimet | Asphage | Ausbetmin | Avrophage | Bariphage | Betaform | Biophage | Bleorformin | Chanformin | Cidophage | Degluco | Diabetmin | Diapil | Dibinorm | Dicheck | Eden metformin | Forbetic | Gluconorm sr | Glucophage | Glucophage xr | Gluformin | Glumin | Glyformin | Hegluphage | Hiclomin | Juformin | Lemformin | Lifeback metformin | Lizophage | Meem metformin hydrochloride | Meem metformin hydrochloride sr | Mephage | Metforal | Metfordeal | Metformin | Metfosyn | Metfosyn sr | Metmin | Metsure | Nevox | Osworth metformin | Panfor sr | Pivox | Saimet | Sakophage | Stermet | Sucrophage | Sunshine coopharm metformin | T&amp;g metformin | Taformin | Triumvirate metformin | Vpl metformin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Glucient sr | Glucophage | Metformine focus | Metformine hcl | Metformine Hcl Actavis | Metformine hcl Alpharma | Metformine hcl aurobindo | Metformine hcl cf | Metformine hcl elc | Metformine Hcl Merck | Metformine hcl mylan | Metformine hcl PCH | Metformine hcl ratiopharm | Metformine hcl sandoz | Metformine hcl teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Glucophage | Metformin | Metformin actavis | Metformin karo pharma | Metformin medical valley | Metformin mylan | Metformin orifarm | Metformin Pfizer | Metformin sandoz | Metformin vitabalans | Metformin weifa | Orabet</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">3m metformin | Apo metformin | Diabex | Glucomet | Glucophage | Metabet sr | Metchek | Metex xr | Metformin mylan | Metformin viatris | Metomin</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Omformin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dexide | Diabensin | Diabetformin | Diabetil | Diabicare | Diabicare xr | Diaburin ap | Dimefor | Disformin | Ditformin | Emnorm | Formilab | Glicenex | Glicomed | Glucaminol | Glucinex | Glucolight | Glucophage | Glucophage xr | Glucotrin | Glunor | Glupac sr | Hipoglucin | Liposol lp | Medfort | Megumina | Metforbiotech | Metformek | Metformina | Metformina clorhidrato | Metfortabs | Metfortabs xr | Metglu | Metphine | Oromet | Quexel | Stalmin er</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ansures | Asamet | Denkaform | Diafat | Diamet | Diametin | Dimet | Euform | Formet | Formetin | Fornidd | Glucoform | Glucogen | Glucomed | Glucomet | Glucophage | Glucopres | Gludin | Glumet | Glyformet | HovidEuform | HovidEuform XR | Humamet | I-max | Insumed | Insunex | Melmet | Metfor xr | Metformin | Metformin Boie | Metkem | Metta | Mymet | Neoform | Nidcor | Normax | Panfor | Paradim | Proglutrol | Ritemed metformin hcl | Saphormin | Srimet | Sucranorm | Sugadrop | Vimetrol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adformin | Alformin | Atfromin xr | Biguanil | Comet | Diabimin | Diabin | Diamet er | Dowphage er | Eloglipten xr | Glovin | Gluchk | Glucomin | Gluconil | Glucophage | Glumet | Glumetza | Glumin | Glymo xr | Hilomet | Lisformin | Lowglo xr | Mephage | Meteor | Metfor | Metformin | Metformina | Metmin | Metphage | Metscot | Metscot xr | Neodipar | Neodipar sr | Neophage | Newformet | Regain XR | Robustin | Sugamet | Tabrophage | Xormet xr</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Avamina | Avamina sr | Diformin | Etform | Formetic | Glucophage | Gluformin | Metcrean | Metcrean xr | Metforatio | Metformax | Metformax 1000 | Metformin | Metformin bluefish | Metformin vitabalans | Metifor | Siofor | Symformin xr | Zenofor sr</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Glucophage | Glucophage xr | Metformin | Metformin er | Metformin HCL | Riomet</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Diabay | Glucophage | Metformina | Metformina aurovitas | Metformina basi | Metformina bluefish | Metformina labesfal | Metformina Mylan | Metformina parke davis | Metformina tolife | Risidon | Stagid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bentic | Ceptor | Clorhidrato de metformina | D.b.i. | D.b.i. ap | Diabemix | Diabetol | Diaformina | Diaformina lp | Glicomed | Gluformina | Hipoglucin | Hipoglux | Kirum | Metformin fapasa | Metformina dallas | Metformina dutriec | Metformina eximfarma | Metformina heisecke | Metformina intas | Metformina milefar | Metformina millet | Metformina mintlab | Metiogen | Nestyl | Quexel | Salidiab ap | Spasin nf | Timet | Tolemina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Amophage | Dialon | Diaphage | Diaphage SR | Dimet | Emiphage | Formit | Glucare | Glucolife XR | Glucophage | Glucophage XR | Glymet | Metaphage | Metfor | Neomet | Omformin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Diaformin | Diguan | Dipimet | Glucophage | Glucophage xr | Metformin | Metformin accord | Siofor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bagomet | Diaformin od | Dianormet | Diasfor | Formetin | Formetin long | Formin pliva | Gliformin | Gliformin prolong | Gliminfor | Glucophage | Glyformin | Langerin | Merifatin | Merifatin mb | Metadien | Metfogamma | Metformin | Metformin avexima | Metformin long | Metformin long canon | Metformin ms | Metformin mv | Metformin mv teav | Metformin richter | Metformin sandoz | Metformin sanofi | Metformin teva | Metformin vertex | Metforvel | Nova met | Novoformin | Siofor | Sophamet | Vero metformin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dialon | Diaphage | Formit | Formit xr | Glucare | Glucare xr | Glucophage | Melbin | Metaphage | Metfor | Metformin hexal | Omformin | Pms-metformin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Glucophage | Metformin actavis | Metformin amneal | Metformin aurobindo | Metformin biochemie | Metformin bluefish | Metformin ebb | Metformin eql pharma | Metformin hexal | Metformin meda | Metformin medical valley | Metformin mylan | Metformin orifarm | Metformin sandoz | Metformin stada | Metformin teva | Metformin vitabalans | Metformin zentiva | Mitforgen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Auro metformin | Diabetmin | Diaformin | Diamet | Formet | Glucomet | Glucophage | Glycomet | Glycoran | Glyformin | Metforal | Metformin | Metphage | Oralmet</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aglurab | Glucophage | Glucophage xr | Gluformin | Metformin vitabalans | Siofor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Diareg | Diformin | Glucophage | Gluformin | Glumetsan | Metfogamma | Metformin | Metformin bluefish | Metformin mylan | Metformin mylan xr | Metformin sandoz | Metformin teva | Metformin vitabalans | Mirovian | Mirovian xr | Normaglyc | Siofor | Siofor SR</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Bgmet</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Ficonax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ammiformin | Deson | Deson pr | Diaformin | Diamet | Diaslim | Dpp | Formin-500 | Formin-850 | Formon | Gluco | Glucobe | Glucoformin | Glucoles | Glucolyte | Glucomet | Glucomin | Gluconase | Glucono | Glucophage | Glucophage xr | Gluformin | Glustress | Glutabloc | Gluzolyte | Maformin | Maxformin 850 | Me-f | Meformed | Melmet | Metfama | Metfor-500 | Metfor-850 | Metforin | Metformin | Metformin bdc | Metfron | Metpharma | Metstarmin | Miformin | Neoformin | Pinformin | Pocophage | Pocophage-a | Poli-formin | Prophage | Serformin | Siamformet</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Brot | Diabiphage | Diabitos | Dialon | Formidiab | Glucophage | Glyformin | Mefor | Metforal | Metformine winthrop | Metformine zentiva | Stagid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Diabest | Diaformin | Glange | Glifor | Glinext | Glucophage | Glucotard | Gluforce | Gluformin | Glukofen | Insufor | Matofin | Metforix | Metodel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anformin | Ankomin | Ansures | Antigluco | Anxofin | Anxoken | Bentomin | Betaform | Bicanol | Bigsens | Diabetmin | Diaformin | Eutomin | Glibudon | Glibudon xr | Glubin | Glucobin | Glucofit | Glucomin | Glucomine | Glucophage | Glumet | Glupin | Glycoran | Glyformin | Gufre | Ilimin | Kotang | Lial | Liformin | Loditon | Lvtangsu | Meforin | Meglucon | Melbin | Metdia | Metfopin | Metformin | Meto | Metose | Metsafe | Simelin | Tensomin | Uformin | Urimin | Volv</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bagomet | Diaformin | Diaformin sr | Dianormet | Glucophage xr | Glucowin xr | Glycomet | Glycomet sr | Insufor | Mefarmil | Megliphort | Metafor | Metafora sr | Metamin | Metamin sr | Metfogamma | Metformin | Metformin indar | Metformin sandoz | Metformin sanofi | Metformin teva | Metformin zentiva | Panfor | Siofor</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aartmin | Agoformin | Asformin | Bigomet | Brot | Diabetmin | Diabetmin retard | Diabetmin xr | Dialon | Exermet | Formin | Formit | Glucomet | Glucophage | Glycomet | Glyformin | Glygen 500 | Informet | Lofin | M forlin | Metfil | Metfokant | Metformin | Metformin denk | Metsafe | Mf day | Panfor | Renformin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Diaformina | Diaformina lp | Glucaminol | Medobis | Medobis ap | Metformed | Metformed gr | Metformina clorhidrato | Metformina opko | Quexel | Resolut</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Canfir | Clormin | Diaformina | Diamenil | Dimefor | Ficonax | Glafornil | Gletfor | Gliformin | Glubetic | Glucaminol | Glucofage | Glucozim | Glunovag | Maveral | Metfil | Metfor | Metformin | Metformina | Metformina hcl | Metormin | Quexel</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Dh metglu xr | Fordia mr | Glucofast | Glucofine | Gludipha | Glumeform | Gluphakaps | Indform | Metsav | Nalordia | Pymetphage</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Metformin | Apex-metformin | Auro metformin | Austell metformin | Bigsens | Cadbower | Carbuce | Diabetmin | Diamin | Diaphage | Glucomet xr | Gluconorm | Glucophage | Glucophage xr | Indo Metformin | Mengen | Merck-metformin | Metchek | Metforal | Metformin | Metformin accord | Metformin alkem | Metformin pharmc | Metformin teva | Metformin xr 500 mg accord | Metored | Rolab-metformine | Romidab</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Auro metformin | Bgmet | Diabetmin | Dimet | Emnorm | Erimet | Formin | Glucophage | Glyciphage | Lofin | Metaphage | Metchek | Metfil | Metformin | Metformin denk | Ranophage | Xmet</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Metfin | Metformin | Metsafe | Metta | Ranophage</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15915567">
<a name="15915567"></a>American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. <i>Endocr Pract</i>. 2005;11(2):126-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15915567/pubmed" id="15915567" target="_blank">15915567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. https://www.acr.org/Clinical-Resources/Contrast-Manual. Published 2021. Accessed July 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2020">
<a name="ADA.2020"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2020. <i>Diabetes Care</i>. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2022. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed October 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964865">
<a name="34964865"></a>American Diabetes Association (ADA). 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. <i>Diabetes Care</i>. 2022;45(suppl 1):S208-S231. doi:10.2337/dc22-S014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34964865/pubmed" id="34964865" target="_blank">34964865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27556593">
<a name="27556593"></a>Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. <i>JAMA Psychiatry</i>. 2016;73(9):928-937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27556593/pubmed" id="27556593" target="_blank">27556593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding. <i>Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900641">
<a name="26900641"></a>Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. <i>J Clin Endocrinol Metab</i>. 2016;101(4):1754-1761. doi:10.1210/jc.2015-3754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/26900641/pubmed" id="26900641" target="_blank">26900641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30425094">
<a name="30425094"></a>Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(12):2648-2668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30425094/pubmed" id="30425094" target="_blank">30425094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9252768">
<a name="9252768"></a>Azzam H, Bergman R, Friedman-Birnbaum R. Lichen planus associated with metformin therapy. <i>Dermatology</i>. 1997;194(4):376. doi:10.1159/000246152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/9252768/pubmed" id="9252768" target="_blank">9252768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626034">
<a name="9626034"></a>Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. <i>Am J Med</i>. 1998;104(5):490-492. doi:10.1016/s0002-9343(98)00088-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/9626034/pubmed" id="9626034" target="_blank">9626034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19709150">
<a name="19709150"></a>Balani J, Hyer SL, Rodin DA, et al. Pregnancy Outcomes in Women With Gestational Diabetes Treated With Metformin or Insulin: A Case-Control Study. <i>Diabet Med</i>. 2009;26(8):798-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/19709150/pubmed" id="19709150" target="_blank">19709150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17490862">
<a name="17490862"></a>Baptista T, Rangel N, Fernández V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. <i>Schizophr Res</i>. 2007;93(1-3):99-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17490862/pubmed" id="17490862" target="_blank">17490862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barbieri.1">
<a name="Barbieri.1"></a>Barbieri R. Metformin for treatment of the polycystic ovary syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Based on manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31821361">
<a name="31821361"></a>Bassols J, Martínez-Calcerrada JM, Osiniri I, et al. Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study. <i>PLoS One</i>. 2019;14(12):e0226303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/31821361/pubmed" id="31821361" target="_blank">31821361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25800925">
<a name="25800925"></a>Béjot Y, Bielefeld P, Guiboux AL, et al. Recurrent encephalopathy induced by metformin in an elderly man. <i>J Am Geriatr Soc</i>. 2015;63(3):620-621. doi:10.1111/jgs.13286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/25800925/pubmed" id="25800925" target="_blank">25800925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34495393">
<a name="34495393"></a>Benham JL, Donovan LE, Yamamoto JM. Metformin in pregnancy for women with type 2 diabetes: a review. <i>Curr Diab Rep</i>. 2021;21(10):36. doi:10.1007/s11892-021-01409-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34495393/pubmed" id="34495393" target="_blank">34495393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15119994">
<a name="15119994"></a>Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. <i>Curr Med Res Opin</i>. 2004;20(4):565-572. doi:10.1185/030079904125003278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15119994/pubmed" id="15119994" target="_blank">15119994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27987248">
<a name="27987248"></a>Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. <i>Diabetes Obes Metab</i>. 2017;19(4):473-481. doi:10.1111/dom.12854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27987248/pubmed" id="27987248" target="_blank">27987248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20452916">
<a name="20452916"></a>Brackett CC. Clarifying metformin's role and risks in liver dysfunction. <i>J Am Pharm Assoc (2003)</i>. 2010;50(3):407-410. doi:10.1331/JAPhA.2010.08090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/20452916/pubmed" id="20452916" target="_blank">20452916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34987051">
<a name="34987051"></a>Brand KMG, Saarelainen L, Sonajalg J, et al. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. <i>BMJ Open Diabetes Res Care</i>. 2022;10(1):e002363. doi:10.1136/bmjdrc-2021-002363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34987051/pubmed" id="34987051" target="_blank">34987051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932841">
<a name="15932841"></a>Briggs GG, Ambrose PJ, Nageotte MP, et al. Excretion of Metformin Into Breast Milk and the Effect on Nursing Infants. <i>Obstet Gynecol</i>. 2005;105(6):1437-1441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15932841/pubmed" id="15932841" target="_blank">15932841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172646">
<a name="34172646"></a>Brodosi L, Petta S, Petroni ML, Marchesini G, Morelli MC. Management of diabetes in candidates for liver transplantation and in transplant recipients. <i>Transplantation</i>. 2022;106(3):462-478. doi:10.1097/TP.0000000000003867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34172646/pubmed" id="34172646" target="_blank">34172646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34571574">
<a name="34571574"></a>Cao Q, Hu Y, Fu J, Huang X, Wu L, Zhang J, Huang W. Gestational metformin administration in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized control studies. <i>J Obstet Gynaecol Res</i>. 2021;47(12):4148-4157. doi:10.1111/jog.15044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34571574/pubmed" id="34571574" target="_blank">34571574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19515536">
<a name="19515536"></a>Carrizo E, Fernández V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. <i>Schizophr Res. </i>2009;113(1):19-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/19515536/pubmed" id="19515536" target="_blank">19515536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24861556">
<a name="24861556"></a>Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. <i>Hum Reprod Update</i>. 2014;20(5):656-669. doi:10.1093/humupd/dmu022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24861556/pubmed" id="24861556" target="_blank">24861556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16418696">
<a name="16418696"></a>Charles B, Norris R, Xiao X, et al. Population Pharmacokinetics of Metformin in Late Pregnancy. <i>Ther Drug Monit</i>. 2006;28(1):67-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16418696/pubmed" id="16418696" target="_blank">16418696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23759461">
<a name="23759461"></a>Chen CH, Huang MC, Kao CF, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. <i>J Clin Psychiatry</i>. 2013;74(5):e424-e430. doi:10.4088/JCP.12m08186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23759461/pubmed" id="23759461" target="_blank">23759461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935775">
<a name="24935775"></a>Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. <i>Diabetes Care</i>. 2014;37(7):2034-2054.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24935775/pubmed" id="24935775" target="_blank">24935775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6369573">
<a name="6369573"></a>Coetzee EJ, Jackson WP. Oral Hypoglycaemics in the First Trimester and Fetal Outcome. <i>S Afr Med J</i>. 1984;65(16):635-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/6369573/pubmed" id="6369573" target="_blank">6369573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27147592">
<a name="27147592"></a>Cooper SJ, Reynolds GP, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. <i>J Psychopharmacol. </i>2016;30(8):717-748. doi:10.1177/0269881116645254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27147592/pubmed" id="27147592" target="_blank">27147592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359574">
<a name="23359574"></a>Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23359574/pubmed" id="23359574" target="_blank">23359574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25574681">
<a name="25574681"></a>Corbett S, Shmorgun D, Claman P, Reproductive Endocrinology Infertility Committee, Healey S, Gysler M. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/25574681/pubmed" id="25574681" target="_blank">25574681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17253562">
<a name="17253562"></a>Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. <i>Cochrane Database Syst Rev</i>. 2007;(1):CD005552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17253562/pubmed" id="17253562" target="_blank">17253562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28055049">
<a name="28055049"></a>Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. <i>Ann Intern Med</i>. 2017;166(3):191-200. doi:10.7326/M16-1901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28055049/pubmed" id="28055049" target="_blank">28055049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10651152">
<a name="10651152"></a>Cubeddu LX, Bönisch H, Göthert M, et al. Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 2000;361(1):85-91. doi:10.1007/s002109900152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/10651152/pubmed" id="10651152" target="_blank">10651152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21846159">
<a name="21846159"></a>Czarnowicki T, Ramot Y, Ingber A, Maly A, Horev L. Metformin-induced leukocytoclastic vasculitis: a case report. <i>Am J Clin Dermatol</i>. 2012;13(1):61-63. doi:10.2165/11593230-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21846159/pubmed" id="21846159" target="_blank">21846159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35733451">
<a name="35733451"></a>Damughatla AR, Surapaneni S, Wadehra A, Kabashneh S, Shanah L. A novel case of metformin-induced pancreatitis in an individual with normal dosing and no underlying chronic kidney disease. <i>Cureus</i>. 2022;14(5):e25116. doi:10.7759/cureus.25116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/35733451/pubmed" id="35733451" target="_blank">35733451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22860242">
<a name="22860242"></a>Das C, Mendez G, Jagasia S, Labbate LA. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. <i>Ann Clin Psychiatry</i>. 2012;24(3):225-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22860242/pubmed" id="22860242" target="_blank">22860242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD clinical practice consensus guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26773926">
<a name="26773926"></a>DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. <i>Metabolism</i>. 2016;65(2):20-29. doi:10.1016/j.metabol.2015.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/26773926/pubmed" id="26773926" target="_blank">26773926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21538144">
<a name="21538144"></a>de Oliveira Baraldi C, Lanchote VL, de Jesus Antunes N, et al. Metformin Pharmacokinetics in Nondiabetic Pregnant Women With Polycystic Ovary Syndrome. <i>Eur J Clin Pharmacol</i>. 2011;67(10):1027-1033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21538144/pubmed" id="21538144" target="_blank">21538144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27716110">
<a name="27716110"></a>de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. <i>BMC Psychiatry</i>. 2016;16(1):341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27716110/pubmed" id="27716110" target="_blank">27716110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29058235">
<a name="29058235"></a>Deden LN, Aarts EO, Aelfers SCW, et al. Risk of metformin-associated lactic acidosis (MALA) in patients after gastric bypass surgery. <i>Obes Surg</i>. 2018;28(4):1080-1085. doi:10.1007/s11695-017-2974-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29058235/pubmed" id="29058235" target="_blank">29058235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diabetes.1">
<a name="Diabetes.1"></a>Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. <i>Can J Diabetes</i>. 2018;42(suppl 1):S1-S325. http://guidelines.diabetes.ca/docs/CPG-2018-full-EN.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):105-114. doi:10.1111/pedi.12737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16785142">
<a name="16785142"></a>Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. <i>Gynecol Endocrinol</i>. 2006;22(5):235-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16785142/pubmed" id="16785142" target="_blank">16785142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25510240">
<a name="25510240"></a>Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. <i>Diabetes</i>. 2015;64(5):1786-1793. doi:10.2337/db14-1388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/25510240/pubmed" id="25510240" target="_blank">25510240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27493135">
<a name="27493135"></a>Dujic T, Zhou K, Tavendale R, Palmer CN, Pearson ER. Effect of serotonin transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin: a GoDARTS study. <i>Diabetes Care</i>. 2016;39(11):1896-1901. doi:10.2337/dc16-0706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27493135/pubmed" id="27493135" target="_blank">27493135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17305787">
<a name="17305787"></a>Ekpebegh CO, Coetzee EJ, van der Merwe L, et al, "A 10-Year Retrospective Analysis of Pregnancy Outcome in Pregestational Type 2 Diabetes: Comparison of Insulin and Oral Glucose-Lowering Agents," <i>Diabet Med</i>, 2007, 24(3):253-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17305787/pubmed" id="17305787" target="_blank">17305787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24842984">
<a name="24842984"></a>Eppenga WL, Lalmohamed A, Geerts AF, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. <i>Diabetes Care</i>. 2014;37(8):2218-2224. doi:10.2337/dc13-3023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24842984/pubmed" id="24842984" target="_blank">24842984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erasmus.1">
<a name="Erasmus.1"></a>Erasmus MC; Health Base Foundation. Metformin assessment report. Beoordelingsrapport metformine. https://www.geneesmiddelenbijlevercirrose.nl/zorgverleners/geneesmiddelen/metformine. Updated March 28, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118196">
<a name="20118196"></a>Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. <i>Drug Metab Dispos</i>. 2010;38(5):833-840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/20118196/pubmed" id="20118196" target="_blank">20118196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22153789">
<a name="22153789"></a>Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on Women's Health Aspects of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. <i>Fertil Steril</i>. 2012;97(1):28-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22153789/pubmed" id="22153789" target="_blank">22153789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32946820">
<a name="32946820"></a>Feig DS, Donovan LE, Zinman B, et al; MiTy Collaborative Group. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. <i>Lancet Diabetes Endocrinol</i>. 2020;8(10):834-844. doi:10.1016/S2213-8587(20)30310-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/32946820/pubmed" id="32946820" target="_blank">32946820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fortamet.1">
<a name="Fortamet.1"></a>Fortamet (metformin) [prescribing information]. Fort Lauderdale, FL: Actavis Laboratories FL, Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11714216">
<a name="11714216"></a>Foss MT, Clement KD. Metformin as a cause of late-onset chronic diarrhea. <i>Pharmacotherapy</i>. 2001;21(11):1422-1424. doi:10.1592/phco.21.17.1422.34430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/11714216/pubmed" id="11714216" target="_blank">11714216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32794179">
<a name="32794179"></a>Fraison E, Kostova E, Moran LJ, et al. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. <i>Cochrane Database Syst Rev.</i> 2020;8(8):CD005552. doi:10.1002/14651858.CD005552.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/32794179/pubmed" id="32794179" target="_blank">32794179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28459036">
<a name="28459036"></a>Gangopadhyay KK, Singh P. Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment. <i>Indian J Endocrinol Metab</i>. 2017;21(2):341-354. doi:10.4103/ijem.IJEM_512_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28459036/pubmed" id="28459036" target="_blank">28459036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract.</i> 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35317103">
<a name="35317103"></a>García-Compeán D, Orsi E, Kumar R, et al. Clinical implications of diabetes in chronic liver disease: diagnosis, outcomes and management, current and future perspectives. <i>World J Gastroenterol</i>. 2022;28(8):775-793. doi:10.3748/wjg.v28.i8.775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/35317103/pubmed" id="35317103" target="_blank">35317103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12545145">
<a name="12545145"></a>Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of Metformin Into Human Milk. <i>Clin Pharmacol Ther</i>. 2003;73(1):71-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/12545145/pubmed" id="12545145" target="_blank">12545145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16879826">
<a name="16879826"></a>Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. <i>Fertil Steril</i>. 2006;86(3):658-663. doi:10.1016/j.fertnstert.2006.02.098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16879826/pubmed" id="16879826" target="_blank">16879826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glucophage.1">
<a name="Glucophage.1"></a>Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glucophage.2">
<a name="Glucophage.2"></a>Glucophage (metformin) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glumetza.1">
<a name="Glumetza.1"></a>Glumetza (metformin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glumetza.3">
<a name="Glumetza.3"></a>Glumetza (metformin) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; September 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glumetza.2">
<a name="Glumetza.2"></a>Glumetza (metformin) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glycon.1">
<a name="Glycon.1"></a>Glycon (metformin) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12436333">
<a name="12436333"></a>Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin into human milk. <i>Diabetologia</i>. 2002;45(11):1509-1514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/12436333/pubmed" id="12436333" target="_blank">12436333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28942807">
<a name="28942807"></a>Handen BL, Anagnostou E, Aman MG, et al. A randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: open-label extension. <i>J Am Acad Child Adolesc Psychiatry</i>. 2017;56(10):849-856.e6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28942807/pubmed" id="28942807" target="_blank">28942807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22679227">
<a name="22679227"></a>Hashmi T. Probable hepatotoxicity associated with the use of metformin in type 2 diabetes. <i>BMJ Case Rep</i>. 2011. doi:10.1136/bcr.04.2011.4092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22679227/pubmed" id="22679227" target="_blank">22679227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26032654">
<a name="26032654"></a>Huang Y, Sun J, Wang X, Tao X, Wang H, Tan W. Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes. <i>J Clin Pharm Ther</i>. 2015a;40(4):461-465. doi:10.1111/jcpt.12290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/26032654/pubmed" id="26032654" target="_blank">26032654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25391019">
<a name="25391019"></a>Huang Y, Sun J, Wang X, Tao X, Wang H, Tan W. Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus. <i>Diabetes Technol Ther</i>. 2015b;17(2):128-133. doi:10.1089/dia.2014.0203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/25391019/pubmed" id="25391019" target="_blank">25391019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30511328">
<a name="30511328"></a>Hui F, Zhang Y, Ren T, Li X, Zhao M, Zhao Q. Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. <i>Eur J Clin Pharmacol</i>. 2019;75(4):437-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30511328/pubmed" id="30511328" target="_blank">30511328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37611751">
<a name="37611751"></a>Hurley-Kim K, Vu CH, Dao NM, et al. Effect of metformin use on vitamin B12 deficiency over time (EMBER): a real-world evidence database study. <i>Endocr Pract</i>. 2023;29(11):862-867. doi:10.1016/j.eprac.2023.06.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/37611751/pubmed" id="37611751" target="_blank">37611751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25536258">
<a name="25536258"></a>Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <i>JAMA</i>. 2014;312(24):2668-2675. doi:10.1001/jama.2014.15298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/25536258/pubmed" id="25536258" target="_blank">25536258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23846733">
<a name="23846733"></a>Jarskog LF, Hamer RM, Catellier DJ, et al; METS Investigators. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. <i>Am J Psychiatry</i>. 2013;170(9):1032-1040. doi:10.1176/appi.ajp.2013.12010127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23846733/pubmed" id="23846733" target="_blank">23846733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30039617">
<a name="30039617"></a>Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD clinical practice consensus guidelines 2018: management of children and adolescents with diabetes requiring surgery [published correction appears in <i>Pediatr Diabetes.</i> 2019;20(1):137]. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):227-236. doi:10.1111/pedi.12733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19432690">
<a name="19432690"></a>Jung EY, Cho HS, Seo JW, et al. Metformin-induced encephalopathy without lactic acidosis in a patient with contraindication for metformin. <i>Hemodial Int</i>. 2009;13(2):172-175. doi:10.1111/j.1542-4758.2009.00358.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/19432690/pubmed" id="19432690" target="_blank">19432690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36628003">
<a name="36628003"></a>Kakarlapudi Y, Kondabolu SK, Tehseen Z, et al. Effect of metformin on vitamin B12 deficiency in patients with type 2 diabetes mellitus and factors associated with it: a meta-analysis. <i>Cureus</i>. 2022;14(12):e32277. doi:10.7759/cureus.32277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/36628003/pubmed" id="36628003" target="_blank">36628003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182265">
<a name="28182265"></a>Kancherla V, Elliott JL Jr, Patel BB, et al. Long-term Metformin Therapy and Monitoring for Vitamin B12 Deficiency Among Older Veterans. <i>J Am Geriatr Soc.</i> 2017;65(5):1061-1066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28182265/pubmed" id="28182265" target="_blank">28182265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22515914">
<a name="22515914"></a>Kang YJ, Bae EJ, Seo JW, et al. Two additional cases of metformin-associated encephalopathy in patients with end-stage renal disease undergoing hemodialysis. <i>Hemodial Int</i>. 2013;17(1):111-115. doi:10.1111/j.1542-4758.2012.00698.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22515914/pubmed" id="22515914" target="_blank">22515914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537521">
<a name="36537521"></a>Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2022;23(8):1468-1477. doi:10.1111/pedi.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/36537521/pubmed" id="36537521" target="_blank">36537521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35074477">
<a name="35074477"></a>Katopodis P, Pappas EM, Katopodis KP. Acid-base abnormalities and liver dysfunction.<i> Ann Hepatol</i>. 2022;27(2):100675. doi:10.1016/j.aohep.2022.100675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/35074477/pubmed" id="35074477" target="_blank">35074477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23175691">
<a name="23175691"></a>Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. <i>J Clin Endocrinol Metab</i>. 2013;98(1):322-329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23175691/pubmed" id="23175691" target="_blank">23175691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease.<i> Kidney Int.</i> 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21606131">
<a name="21606131"></a>Kjøtrød SB, Carlsen SM, Rasmussen PE, et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. <i>Hum Reprod</i>. 2011;26(8):2045-2053. doi:10.1093/humrep/der154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21606131/pubmed" id="21606131" target="_blank">21606131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11832527">
<a name="11832527"></a>Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. <i>N Engl J Med.</i> 2002;346(6):393-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/11832527/pubmed" id="11832527" target="_blank">11832527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30112307">
<a name="30112307"></a>Kumar Y, Kotwal N, Singh Y, Upreti V, Somani S, Hari Kumar KVS. A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. <i>J Family Med Prim Care</i>. 2018;7(3):551-556. doi:10.4103/jfmpc.jfmpc_83_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30112307/pubmed" id="30112307" target="_blank">30112307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29305402">
<a name="29305402"></a>Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. <i>Diabetes Care</i>. 2018;41(3):547‐553. doi:10.2337/dc17-2231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29305402/pubmed" id="29305402" target="_blank">29305402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31980499">
<a name="31980499"></a>Liao MZ, Flood Nichols SK, Ahmed M, et al. Effects of pregnancy on the pharmacokinetics of metformin. <i>Drug Metab Dispos</i>. 2020;48(4):264-271. doi:10.1124/dmd.119.088435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/31980499/pubmed" id="31980499" target="_blank">31980499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21617112">
<a name="21617112"></a>Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. <i>Diabetes Care</i>. 2011;34(6):1431-1437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21617112/pubmed" id="21617112" target="_blank">21617112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lu.2013">
<a name="Lu.2013"></a>Lu M, Zhou Y Cui Y. Possible metformin-induced toe nails disorder. <i>Pharmacology &amp; Pharmacy</i>. 2013;4:275-276.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35149444">
<a name="35149444"></a>Magzoub R, Kheirelseid EAH, Perks C, Lewis S. Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2022;271:38-62. doi:10.1016/j.ejogrb.2022.01.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/35149444/pubmed" id="35149444" target="_blank">35149444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34308109">
<a name="34308109"></a>Martin D, Thaker J, Shreve M, Lamerato L, Budzynska K. Assessment of vitamin B12 deficiency and B12 screening trends for patients on metformin: a retrospective cohort case review. <i>BMJ Nutr Prev Health</i>. 2021;4(1):30-35. doi:10.1136/bmjnph-2020-000193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34308109/pubmed" id="34308109" target="_blank">34308109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23185143">
<a name="23185143"></a>Matson KL, Fallon RM. Treatment of obesity in children and adolescents. <i>J Pediatr Pharmacol Ther</i>. 2012;17(1):45-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23185143/pubmed" id="23185143" target="_blank">23185143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26780750">
<a name="26780750"></a>McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. <i>Diabetologia</i>. 2016;59(3):426-435. doi:10.1007/s00125-015-3844-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/26780750/pubmed" id="26780750" target="_blank">26780750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24343296">
<a name="24343296"></a>McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. <i>JAMA Pediatr</i>. 2014;168(2):178-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24343296/pubmed" id="24343296" target="_blank">24343296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22303523">
<a name="22303523"></a>McIntyre RS, Alsuwaidan M, Goldstein BI, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. <i>Ann Clin Psych. </i>2012;24(1):69-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22303523/pubmed" id="22303523" target="_blank">22303523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi:10.1097/SLA.0b013e3182774522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amneal.1">
<a name="Amneal.1"></a>Metformin hydrochloride extended-release tablet [prescribing information]. Laurelton, NY: Epic Pharma LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31644035">
<a name="31644035"></a>Metformin. In: LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases. <a href="https://www.ncbi.nlm.nih.gov/books/NBK548726/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK548726/</a>. Updated January 21, 2020. Accessed September 26, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/31644035/pubmed" id="31644035" target="_blank">31644035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17327307">
<a name="17327307"></a>Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. <i>Diabetes Care</i>. 2007;30(3):471-478. doi:10.2337/dc06-0618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17327307/pubmed" id="17327307" target="_blank">17327307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24636967">
<a name="24636967"></a>Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. <i>Schizophr Bull.</i> 2014;40(6):1385-1403. doi:10.1093/schbul/sbu030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24636967/pubmed" id="24636967" target="_blank">24636967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10634377">
<a name="10634377"></a>Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. <i>J Clin Endocrinol Metab</i>. 2000;85(1):139-146. doi:10.1210/jcem.85.1.6293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/10634377/pubmed" id="10634377" target="_blank">10634377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12519844">
<a name="12519844"></a>Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. <i>J Clin Endocrinol Metab</i>. 2003;88(1):148-156. doi:10.1210/jc.2002-020997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/12519844/pubmed" id="12519844" target="_blank">12519844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29183107">
<a name="29183107"></a>Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. <i>Cochrane Database Syst Rev</i>. 2017;11(11):CD003053. doi:10.1002/14651858.CD003053.pub6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29183107/pubmed" id="29183107" target="_blank">29183107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36187122">
<a name="36187122"></a>Nabrdalik K, Skonieczna-Żydecka K, Irlik K, et al. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review, meta-analysis and meta-regression of randomized controlled trials. <i>Front Endocrinol (Lausanne)</i>. 2022;13:975912. doi:10.3389/fendo.2022.975912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/36187122/pubmed" id="36187122" target="_blank">36187122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28077460">
<a name="28077460"></a>Nachum Z, Zafran N, Salim R, et al. Glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus: a randomized controlled study. <i>Diabetes Care</i>. 2017;40(3):332-337. doi: 10.2337/dc16-2307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28077460/pubmed" id="28077460" target="_blank">28077460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14561576">
<a name="14561576"></a>Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. <i>Endocr Pract</i>. 2003;9(4):307-309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/14561576/pubmed" id="14561576" target="_blank">14561576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18945920">
<a name="18945920"></a>Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i>. 2009;32(1):193-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18945920/pubmed" id="18945920" target="_blank">18945920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821072">
<a name="11821072"></a>Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. <i>Fertil Steril</i>. 2002;77(2):209-215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/11821072/pubmed" id="11821072" target="_blank">11821072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23068960">
<a name="23068960"></a>Niromanesh S, Alavi A, Sharbaf FR, Amjadi N, Moosavi S, Akbari S. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. <i>Diabetes Res Clin Pract.</i> 2012;98(3):422-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23068960/pubmed" id="23068960" target="_blank">23068960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29174300">
<a name="29174300"></a>Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3year trial. <i>J Diabetes Complications</i>. 2018;32(2):171-178. doi:10.1016/j.jdiacomp.2017.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29174300/pubmed" id="29174300" target="_blank">29174300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34738701">
<a name="34738701"></a>Paavilainen E, Tertti K, Nikkinen H, et al. Metformin versus insulin therapy for gestational diabetes: effects on offspring anthropometrics and metabolism at the age of 9 years: a follow-up study of two open-label, randomized controlled trials. <i>Diabetes Obes Metab</i>. 2022;24(3):402-410. doi:10.1111/dom.14589<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34738701/pubmed" id="34738701" target="_blank">34738701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18783609">
<a name="18783609"></a>Packer CD, Hornick TR, Augustine SA. Fatal hemolytic anemia associated with metformin: a case report. <i>J Med Case Rep</i>. 2008;2:300. doi:10.1186/1752-1947-2-300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18783609/pubmed" id="18783609" target="_blank">18783609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21478461">
<a name="21478461"></a>Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. <i>Diabetes Care</i>. 2011;34(6):1295-1300. doi:10.2337/dc10-2140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21478461/pubmed" id="21478461" target="_blank">21478461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24658791">
<a name="24658791"></a>Pala L, Rotella CM. The "slower" the better. <i>J Endocrinol Invest</i>. 2014;37(5):497-498. doi:10.1007/s40618-014-0065-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24658791/pubmed" id="24658791" target="_blank">24658791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21982727">
<a name="21982727"></a>Palomba S, Falbo A, Carrillo L, et al; METformin in High Responder Italian Group. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. <i>Fertil Steril</i>. 2011;96(6):1384-1390.e4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21982727/pubmed" id="21982727" target="_blank">21982727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23194199">
<a name="23194199"></a>Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. <i>BJOG</i>. 2013;120(3):267-276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23194199/pubmed" id="23194199" target="_blank">23194199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29215149">
<a name="29215149"></a>Panchaud A, Rousson V, Vial T, et al. Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. <i>Br J Clin Pharmacol</i>. 2018;84(3):568-578. doi:10.1111/bcp.13481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29215149/pubmed" id="29215149" target="_blank">29215149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28759403">
<a name="28759403"></a>Pastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, et al. Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial. <i>Pediatrics</i>. 2017;140(1):e20164285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28759403/pubmed" id="28759403" target="_blank">28759403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28865539">
<a name="28865539"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. <i>Fertil Steril</i>. 2017;108(3):426-441. doi:0.1016/j.fertnstert.2017.06.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28865539/pubmed" id="28865539" target="_blank">28865539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23768030">
<a name="23768030"></a>Protti A. One other explanation for hypoglycemia during metformin overdose. <i>Clin Toxicol (Phila)</i>. 2013;51(6):515. doi:10.3109/15563650.2013.808749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23768030/pubmed" id="23768030" target="_blank">23768030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22568883">
<a name="22568883"></a>Protti A, Fortunato F, Monti M, et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. <i>Crit Care</i>. 2012;16(3):R75. doi:10.1186/cc11332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22568883/pubmed" id="22568883" target="_blank">22568883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26872112">
<a name="26872112"></a>Rado J, von Ammon Cavanaugh S. A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. <i>J Clin Psychopharmacol. </i>2016;36(2):163-168. doi:10.1097/JCP.0000000000000469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/26872112/pubmed" id="26872112" target="_blank">26872112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27906695">
<a name="27906695"></a>Ramírez-Bellver JL, Lopez J, Macias E, et al. Metformin-induced generalized fixed drug eruption with cutaneous hemophagocytosis. <i>Am J Dermatopathol</i>. 2017;39(6):471-475. doi:10.1097/DAD.0000000000000800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27906695/pubmed" id="27906695" target="_blank">27906695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28736433">
<a name="28736433"></a>Rhee CM, Kalantar-Zadeh K. Diabetes mellitus: complex interplay between metformin, AKI and lactic acidosis. <i>Nat Rev Nephrol</i>. 2017;13(9):521-522. doi:10.1038/nrneph.2017.105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28736433/pubmed" id="28736433" target="_blank">28736433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Riomet.1">
<a name="Riomet.1"></a>Riomet ER (metformin) suspension [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Riomet.2">
<a name="Riomet.2"></a>Riomet (metformin) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Robertson.1">
<a name="Robertson.1"></a>Robertson RP. Prevention of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19846793">
<a name="19846793"></a>Rowan JA, Gao W, Hague WM, et al. Glycemia and Its Relationship to Outcomes in the Metformin in Gestational Diabetes Trial," <i>Diabetes Care</i>, 2010, 33(1):9-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/19846793/pubmed" id="19846793" target="_blank">19846793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18463376">
<a name="18463376"></a>Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes [published correction appears in <i>N Engl J Med</i>. 2008;359(1):106]. <i>N Engl J Med.</i> 2008;358(19):2003-2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18463376/pubmed" id="18463376" target="_blank">18463376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rudnick.1">
<a name="Rudnick.1"></a>Rudnick MR, Davenport MS. Prevention of contrast-induced acute kidney injury associated with computed tomography. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20393934">
<a name="20393934"></a>Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. <i>Cochrane Database Syst Rev</i>. 2010;2010(4):CD002967. doi:10.1002/14651858.CD002967.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/20393934/pubmed" id="20393934" target="_blank">20393934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16644645">
<a name="16644645"></a>Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. <i>Diabetes Care</i>. 2006;29(5):1105-1107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16644645/pubmed" id="16644645" target="_blank">16644645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30017588">
<a name="30017588"></a>Scherneck S, Schlinke N, Beck E, et al. Pregnancy outcome after first-trimester exposure to metformin: a prospective cohort study. <i>Reprod Toxicol</i>. 2018;81:79-83. doi:10.1016/j.reprotox.2018.07.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30017588/pubmed" id="30017588" target="_blank">30017588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes.</i> 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33576490">
<a name="33576490"></a>Skibinska M, Zurawska-Klis M, Krekora M, Cypryk K. Metformin administration during pregnancy - current insight. <i>Ginekol Pol</i>. 2021;92(1):46-50. doi:10.5603/GP.a2020.0149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/33576490/pubmed" id="33576490" target="_blank">33576490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31960986">
<a name="31960986"></a>Smith FC, Stocker SL, Danta M, et al. The safety and pharmacokinetics of metformin in patients with chronic liver disease. <i>Aliment Pharmacol Ther</i>. 2020;51(5):565-575. doi:10.1111/apt.15635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/31960986/pubmed" id="31960986" target="_blank">31960986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16675650">
<a name="16675650"></a>Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. <i>Am J Health Syst Pharm</i>. 2006;63(10):929-938. doi:10.2146/ajhp050500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16675650/pubmed" id="16675650" target="_blank">16675650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27056044">
<a name="27056044"></a>Steber CJ, Perkins SL, Harris KB. Metformin-induced fixed-drug eruption confirmed by multiple exposures. <i>Am J Case Rep</i>. 2016;17:231-234. doi:10.12659/ajcr.896424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27056044/pubmed" id="27056044" target="_blank">27056044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28359099">
<a name="28359099"></a>Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2017;102(3):709-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28359099/pubmed" id="28359099" target="_blank">28359099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537520">
<a name="36537520"></a>Sundberg F, deBeaufort C, Krogvold L, et al. ISPAD clinical practice consensus guidelines 2022: managing diabetes in preschoolers. <i>Pediatr Diabetes</i>. 2022;23(8):1496-1511. doi:10.1111/pedi.13427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/36537520/pubmed" id="36537520" target="_blank">36537520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16501038">
<a name="16501038"></a>Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. <i>Hum Reprod</i>. 2006;21(6):1416-1425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/16501038/pubmed" id="16501038" target="_blank">16501038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30033227">
<a name="30033227"></a>Teede HJ, Misso ML, Costello MF, et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. <i>Fertil Steril</i>. 2018;110(3):364-379. doi: 10.1016/j.fertnstert.2018.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30033227/pubmed" id="30033227" target="_blank">30033227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087796">
<a name="31087796"></a>Teede H, Tassone EC, Piltonen T, et al. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses. <i>Clin Endocrinol (Oxf)</i>. 2019;91(4):479-489. doi:10.1111/cen.14013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/31087796/pubmed" id="31087796" target="_blank">31087796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23020608">
<a name="23020608"></a>Tertti K, Ekblad U, Koskinen P, Vahlberg T, Rönnemaa T. Metformin vs insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. <i>Diabetes Obes Metab</i>. 2013;15(3):246-251. doi:10.1111/dom.12017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23020608/pubmed" id="23020608" target="_blank">23020608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18795211">
<a name="18795211"></a>Tertti K, Ekblad U, Vahlberg T, et al, "Comparison of Metformin and Insulin in the Treatment of Gestational Diabetes: A Retrospective, Case-Control Study," <i>Rev Diabet Stud</i>, 2008, 5(2):95-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18795211/pubmed" id="18795211" target="_blank">18795211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18243179">
<a name="18243179"></a>Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. <i>Fertil Steril</i>. 2008;89(3):505-522. doi:10.1016/j.fertnstert.2007.09.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/18243179/pubmed" id="18243179" target="_blank">18243179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23704676">
<a name="23704676"></a>TODAY Study Group. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. <i>Diabetes Care</i>. 2013;36(6):1765-1771.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/23704676/pubmed" id="23704676" target="_blank">23704676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33347618">
<a name="33347618"></a>Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. <i>Cochrane Database Syst Rev</i>. 2020;12(12):CD006105. doi:10.1002/14651858.CD006105.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/33347618/pubmed" id="33347618" target="_blank">33347618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28632874">
<a name="28632874"></a>US Preventive Services Task Force, Grossman DC, Bibbins-Domingo K, et al. Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. <i>JAMA</i>. 2017;317(23):2417-2426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/28632874/pubmed" id="28632874" target="_blank">28632874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29748932">
<a name="29748932"></a>van Rongen A, van der Aa MP, Matic M, et al. Increased metformin clearance in overweight and obese adolescents: a pharmacokinetic substudy of a randomized controlled trial. <i>Paediatr Drugs</i>. 2018;20(4):365-374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29748932/pubmed" id="29748932" target="_blank">29748932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30600626">
<a name="30600626"></a>Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. <i>World Psychiatry</i>. 2019;18(1):53-66. doi:10.1002/wps.20614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30600626/pubmed" id="30600626" target="_blank">30600626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15866611">
<a name="15866611"></a>Vanky E, Zahlsen K, Spigset O, et al, "Placental Passage of Metformin in Women With Polycystic Ovary Syndrome," <i>Fertil Steril</i>, 2005, 83(5):1575-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/15866611/pubmed" id="15866611" target="_blank">15866611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20500959">
<a name="20500959"></a>Vause TD, Cheung AP, Sierra S, et al. Ovulation induction in polycystic ovary syndrome: No. 242, May 2010. <i>Int J Gynaecol Obstet</i>. 2010;111(1):95-100. <i>Erratum in:</i>
<i>J Obstet Gynaecol Can</i>. 2011;33(1):12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/20500959/pubmed" id="20500959" target="_blank">20500959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27574928">
<a name="27574928"></a>Voore P, Odigwe C, Mirrakhimov AE, Rifai D, Iroegbu NA. DRESS syndrome following metformin administration: a case report and review of the literature. <i>Am J Ther</i>. 2016;23(6):e1970-e1973. doi:10.1097/MJT.0000000000000292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27574928/pubmed" id="27574928" target="_blank">27574928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30911997">
<a name="30911997"></a>Wang A, Mo T, Li Q, Shen C, Liu M. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. <i>Endocrine</i>. 2019;64(2):220-232. doi:10.1007/s12020-019-01860-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30911997/pubmed" id="30911997" target="_blank">30911997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22398127">
<a name="22398127"></a>Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. <i>Schizophr Res. </i>2012;138(1):54-57. doi:10.1016/j.schres.2012.02.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/22398127/pubmed" id="22398127" target="_blank">22398127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30070925">
<a name="30070925"></a>Warnakulasuriya LS, Fernando MMA, Adikaram AVN, et al. Metformin in the management of childhood obesity: a randomized control trial. <i>Child Obes</i>. 2018;14(8):553-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30070925/pubmed" id="30070925" target="_blank">30070925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29330714">
<a name="29330714"></a>Weersink RA, Bouma M, Burger DM, et al. Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis. <i>Drug Saf</i>. 2018;41(6):603-613. doi:10.1007/s40264-017-0635-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29330714/pubmed" id="29330714" target="_blank">29330714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35344380">
<a name="35344380"></a>Wensink MJ, Lu Y, Tian L, et al. Preconception antidiabetic drugs in men and birth defects in offspring : a nationwide cohort study. <i>Ann Intern Med</i>. 2022;175(5):665-673. doi:10.7326/M21-4389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/35344380/pubmed" id="35344380" target="_blank">35344380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Initial management of blood glucose in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 1, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.2">
<a name="Wexler.2"></a>Wexler DJ. Metformin in the treatment of adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124139">
<a name="20124139"></a>Wilson DM, Abrams SH, Aye T, et al. Glaser Pediatric Research Network Obesity Study Group. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. <i>Arch Pediatr Adolesc Med</i>. 2010;164(2):116-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/20124139/pubmed" id="20124139" target="_blank">20124139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744629">
<a name="32744629"></a>Wu Y, Tu M, Huang Y, Liu Y, Zhang D. Association of metformin with pregnancy outcomes in women with polycystic ovarian syndrome undergoing in vitro fertilization: a systematic review and meta-analysis.<i> JAMA Netw Open</i>. 2020;3(8):e2011995. doi:10.1001/jamanetworkopen.2020.11995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/32744629/pubmed" id="32744629" target="_blank">32744629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21228310">
<a name="21228310"></a>Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. <i>Diabetes</i>. 2011;60(2):477-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/21228310/pubmed" id="21228310" target="_blank">21228310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26335661">
<a name="26335661"></a>Yee SW, Lin L, Merski M, et al. Prediction and validation of enzyme and transporter off-targets for metformin. <i>J Pharmacokinet Pharmacodyn</i>. 2015;42(5):463-475. doi:10.1007/s10928-015-9436-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/26335661/pubmed" id="26335661" target="_blank">26335661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34198358">
<a name="34198358"></a>Yen FS, Huang YH, Hou MC, et al. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. <i>Br J Clin Pharmacol</i>. 2022;88(1):311-322. doi:10.1111/bcp.14970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34198358/pubmed" id="34198358" target="_blank">34198358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34401527">
<a name="34401527"></a>Yip TC, Chan RNC, Wong VW, et al. Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Sci Rep</i>. 2021;4(3):e352. doi:10.1002/hsr2.352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/34401527/pubmed" id="34401527" target="_blank">34401527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999228">
<a name="29999228"></a>Zeitler P, Arslanian S, Fu J, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):28-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/29999228/pubmed" id="29999228" target="_blank">29999228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27603343">
<a name="27603343"></a>Zeng XL, Zhang YF, Tian Q, Xue Y, An RF. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. <i>Medicine (Baltimore)</i>. 2016;95(36):e4526. doi:10.1097/MD.0000000000004526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/27603343/pubmed" id="27603343" target="_blank">27603343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24798175">
<a name="24798175"></a>Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i>. 2014;60(6):2008-2016. doi:10.1002/hep.27199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24798175/pubmed" id="24798175" target="_blank">24798175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24263160">
<a name="24263160"></a>Zheng L. Metformin as a rare cause of drug-induced liver injury, a case report and literature review. <i>Am J Ther</i>. 2016;23(1):e315-e317. doi:10.1097/MJT.0000000000000007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/24263160/pubmed" id="24263160" target="_blank">24263160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26280837">
<a name="26280837"></a>Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized, placebo-controlled trials. <i>J Clin Psychopharmacol. </i>2015;35(5):499-509. doi:10.1097/JCP.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/26280837/pubmed" id="26280837" target="_blank">26280837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30546312">
<a name="30546312"></a>Zhuo C, Xu Y, Liu S, et al. Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. <i>Front Pharmacol.</i> 2018;9:1393. doi:10.3389/fphar.2018.01393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metformin-pediatric-drug-information/abstract-text/30546312/pubmed" id="30546312" target="_blank">30546312</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12589 Version 909.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
